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Introduction 1
1. Introduction 
Chronic kidney disease (CKD) in human beings is a major cause of morbidity and 
mortality worldwide. It is characterized by relentless progressive scarring of renal 
parenchyma that results in end-stage renal disease (ESRD) with the need for dialysis 
or transplantation (Fogo, 2006). The understanding of the underlying mechanisms of 
injury has been a major challenge for decades and is now urgently needed in the 
view of dramatically increasing incidence of CKD (Zoja et al., 2006). The variety of 
renal diseases implies various mechanisms leading to altered expression of proteins 
in the different renal microstructures. Therefore, analysis of the renal proteome 
during relevant disease states is crucial for a better understanding of the complexity 
of the pathogenesis and pathophysiology of the different renal diseases. The 
development of progressive glomerulosclerosis is a hallmark of CKD and represents 
a highly relevant problem in nephrology. Independent of disease specific initial 
pathogenic insults, the earliest stages of glomerulosclerosis are characterised by 
common morphological and functional alterations of the glomeruli. Glomerular 
hypertrophy and the subsequent development of albuminuria were both identified as 
key determinants of the progression of disease (Fogo and Ichikawa, 1991; Remuzzi, 
1995). In the present study the glomerular proteome of two different mouse models 
of nephropathy was analysed at defined early stages of glomerulosclerosis in order 
to identify proteins with potential pathogenetic or diagnostic significance: Growth 
hormone (GH) transgenic mice are a well characterised model for progressive 
glomerulosclerosis. Transgenic mice expressing a dominant negative glucose-
dependent insulinotropic polypeptide receptor (GIPRdn) represent a model for 
diabetes-associated glomerular lesions. Because glomeruli represent only about 
2 - 4 % of the whole kidney volume (Artacho-Perula et al., 1993; Nyengaard and 
Bendtsen, 1992; Wanke, 1996), a subproteome approach targeting isolated renal 
glomeruli was the method of choice. The first objective of the study was to identify 
differentially abundant proteins in transgenic mice as compared to wild-type controls 
within each analysed group and analysed disease stage. The overall aim was to 
reveal, whether molecular signatures detected by the quantitative profiling in both 
analysed mouse models would show similarities and if they would point to shared 
molecular mechanisms of disease.  
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2. Literature review 
2.1 Chronic renal failure 
Chronic kidney disease (CKD) in human beings is a major cause of morbidity and 
mortality worldwide (Fogo, 2006). Increasing numbers of patients are affected by 
CKD. This rise is reflected in the increasing number of people with end-stage renal 
disease (ESRD) treated by renal replacement therapy (RRT) – dialysis or 
transplantation, and is threatening to reach epidemic proportions over the next 
decade (El Nahas and Bello, 2005). Independent of various initial insults, the 
progression to ESRD is a common outcome in chronic nephropathies (Remuzzi et 
al., 2006). Worldwide, the number of patients undergoing treatment for ESRD was 
estimated to have reached 1.9 million by the end of 2005 with yearly growth rates 
about 6 – 7 % (Grassmann et al., 2006). In the United States prevalence counts of 
ESRD are expected to increase by 85 % from 382,000 in 2000 to over 700,000 in the 
year 2015 and the number of incident ESRD patients is expected to increase by 
about 44 % to 136,000 in 2015, respectively (Gilbertson et al., 2005). In the 
European Union there are currently approximately 436,000 RRT patients as 
compared to ~382,000 patients in 2002, with Germany counting for ~87,000 patients 
as compared to 75,000 in 2002 (ERA-EDTA-Registry, 2007; Frei and Schober-
Halstenberg, 2006). This dramatic increase represents not only a major public health 
problem, but also an economic challenge due to very costly renal replacement 
therapies. In Europe, dialysis alone takes up about 2 % of health care budgets, with 
only a small proportion (< 0.01 %) of the population needing treatment (De Vecchi et 
al., 1999). Counting for about half of the cases diabetic nephropathy is the major 
cause of chronic renal failure (Mitka, 2005). Taking into account that worldwide more 
than 180 million people suffer from diabetes and the number is likely to be more than 
double in 2030, it will be of even more importance (www.who.int/diabetes). CKD is 
characterised by relentless progressive scarring of renal parenchyma that ultimately 
results in ESRD with the need for dialysis or transplantation (Fogo, 2006). The 
hallmarks of progressive nephropathies are glomerulosclerosis, tubular atrophy, and 
interstitial fibrosis (Fogo, 1999; Zoja et al., 2006). The majority of diseases which 
progress to chronic renal failure in humans as well as in laboratory animals begin at 
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the glomerulus (Klahr et al., 1988; Kriz and LeHir, 2005). Therefore, the focus in the 
following section will be laid on glomerulosclerosis. 
2.2 Progressive glomerulosclerosis 
The term “glomerulosclerosis” is commonly used to designate glomerular scarring. It 
describes a pathologic diagnosis based exclusively on morphologic criteria and 
contains no statement about etiology or pathogenesis of the lesion. 
Glomerulosclerosis refers to a variety of glomerular lesions including increases in 
mesangial matrix, collapse and obliteration of capillary lumina, accumulation of 
hyaline, and synechial attachments to Bowman’s capsule (Floege et al., 1992; 
Romen, 1976; Schwartz and Lewis, 1985; Striker, 1993). Glomerulosclerosis may be 
“diffuse“, if more than 80 % of investigated glomeruli are altered, whereas it is called 
“focal”, if only some glomeruli are involved. The terms “global” or “segmental” 
glomerulosclerosis stand for either the complete or partial sclerosis of a single 
glomerulus (Churg and Sobin, 1982).  
Glomerulosclerotic changes have been documented extensively in literature of 
human nephrology as well as pathology. In humans, the so-called primary or 
idiopathic focal segmental glomerulosclerosis (FSGS) is an important cause of the 
idiopathic nephrotic syndrome (Goldszer et al., 1984) and takes up a special position 
in the group of sclerosing glomerulopathies. Alongside this clinical entity (Waldherr 
and Derks, 1989) exists the frequently occurring group of secondary 
glomeruloscleroses. In this form glomerulosclerosis develops in association with a 
variety of systemic or renal diseases (Goldszer et al., 1984). Systemic diseases in 
the context of which glomerulosclerosis can occur can be grouped into broad 
categories, such as vascular diseases (e.g. essential hypertension), metabolic 
disorders (e.g. diabetes mellitus), hereditary diseases (e.g. Fabry’s disease), and 
systemic immunological diseases (e.g. systemic lupus erythematosus). Among them 
diabetes mellitus is the most common cause of glomerulosclerosis in humans (Striker 
et al., 1995). Different forms of diffuse glomerulonephritis can also result in diffuse 
glomerulosclerosis (Klahr et al., 1988; Rennke and Klein, 1989; Schreiner, 1990). A 
once established chronic renal insufficiency tends to progress to end-stage renal 
failure which is characterised by progressive glomerulosclerosis independent of the 
nature of the initiating nephropathy (el Nahas, 1989). Progressive glomerulosclerosis 
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therefore represents a highly relevant problem in nephrology and the study of its 
pathogenesis is a key issue in nephrologic research. 
2.3 Pathogenesis of glomerulosclerosis 
2.3.1 Glomerular hypertrophy 
Concerning the pathogenesis of progressive glomerulosclerosis several pathogenetic 
concepts with a uniform pathomechanism which determines the development of 
glomerulosclerosis exist. But they differ in the nature of the initiating event. In the 
early nineteen eighties it was postulated that adaptive glomerular hyperperfusion and 
hyperfiltration would initiate glomerulosclerosis in remnant glomeruli after glomerular 
ablation (Brenner et al., 1982). Later the initial hypothesis was revised and increased 
glomerular capillary pressure was found to be a key mediator of progressive renal 
sclerosis (Anderson et al., 1985). However, there was some doubt on the universal 
validity of this hypothesis. Yoshida and colleagues did not find a positive correlation 
between the magnitude of the early glomerular capillary pressure and the 
subsequent development of glomerulosclerosis in rats with remnant kidneys (Yoshida 
et al., 1988). They came to the conclusion that glomerular hypertension alone does 
little to promote glomerulosclerosis. It was postulated that not hemodynamics but 
glomerular hypertrophy has a direct causal impact on the development of 
glomerulosclerosis, because a strong positive correlation could be shown between 
the glomerular size and the degree of sclerosis (Yoshida et al., 1989). This was also 
supported by a number of other studies (Daniels and Hostetter, 1990; Fries et al., 
1989). The importance of glomerular hypertrophy in the pathogenesis of 
glomerulosclerosis has been documented by several authors (Fogo and Ichikawa, 
1991; Klahr et al., 1988; Olson and Heptinstall, 1988). The linkage between 
glomerular hypertrophy and sclerosis has been demonstrated in numerous diseases 
in humans as well as in experimental animal models (Fogo, 2000). Initial disease-
specific pathogenic insults lead to a loss of functioning nephrons resulting in 
glomerular hypertrophy which initiates glomerulosclerosis. This represents the entry 
in a vicious cycle, because progressive glomerulosclerosis results in a further loss of 
nephrons. Finally, end stage renal disease develops (Ichikawa et al., 1991). In FSGS 
and diabetes glomerular hypertrophy occurs without prior nephron loss. In these 
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diseases the initial pathogenic mechanisms itself are linked to glomerular 
hypertrophy (Fogo and Ichikawa, 1989). The first obvious and earliest changes in the 
course of diabetes associated kidney lesions after manifestation of diabetes are renal 
and glomerular hypertrophy (Lehmann and Schleicher, 2000). Glomerular 
hypertrophy can be detected in experimentally induced diabetes within four days 
(Osterby and Gundersen, 1980). It is essential, that glomerular hypertrophy not only 
is a symptom of diabetes associated renal changes, but plays a vital role in the 
pathogenesis of diabetic glomerulosclerosis (Fogo and Ichikawa, 1989; Wolf, 2000). 
It is seen as a prerequisite rather than a consequence of hyperfunction (Cortes et al., 
1987). The concept of glomerular hypertrophy is supported by studies on renal 
changes in growth hormone transgenic mice, a well-characterised model of 
progressive glomerulosclerosis (Doi et al., 1990; Wanke et al., 1991) (see 2.4.1).  
Glomerular hypertrophy is characterised by hypertrophy and hyperplasia of 
mesangial and endothelial cells whereas podocytes only show hypertrophy and no 
change in cell number (Fogo, 1999; Wiggins et al., 2005). Due to glomerular 
hypertrophy a damage of podocytes occurs, causing disturbances in the glomerular 
filtration barrier (Kriz et al., 1994; Wanke et al., 2001).  
2.3.2 Podocyte damage 
Kidney function depends on an intact glomerular filtration barrier and podocytes are 
crucially involved in establishing the specific properties of the glomerular filter 
(Pavenstadt et al., 2003). The latter consists of the fenestrated endothelium, the 
glomerular basement membrane, and the slit diaphragm that connects interdigitating 
podocyte foot processes. Under physiological conditions it is freely permeable by 
water and small solutes, but not for proteins of the size of albumin and larger. 
Podocytes are highly differentiated neuron-like epithelial cells which have a limited 
capacity for cell replication (Wiggins et al., 2005). Their ability to adapt to an increase 
in glomerular size is also limited. It has been shown that podocytes react with a 
detailed sequence of structural alterations to the hypertrophy of the glomerulus 
(Wiggins et al., 2005). Early changes include podocyte hypertrophy and foot process 
effacement which represents the most characteristic change in podocyte phenotype 
under a great variety of experimental as well as human glomerulopathies (Shirato et 
al., 1996; Wanke et al., 2001). Recent studies have shown that podocyte injury is a 
trigger for glomerulosclerosis and plays a key role in the progression of 
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glomerulosclerosis as well as tubulointerstitial lesions (Ichikawa et al., 2005; Kriz, 
2002). The filtration of serum proteins into the Bowman’s space is not only a result 
but may also be a cause of podocyte damage (Ichikawa et al., 2005). 
2.3.3 Proteinuria 
Under physiological conditions proteins with a molecular size like albumin (67 kDa) 
and larger are not able to pass the glomerular filtration barrier, whereas smaller 
proteins are filtrated and then reabsorbed by the tubular system (Bergstein, 1999). 
Looking on the protein pattern in the urine one can determine the localisation of 
kidney damage. Large proteins indicate a glomerular damage. Podocyte damage 
causes a selective glomerular proteinuria (68 – 150 kDa), damage of glomerular 
basement membranes and mesangium cause an unselective glomerular proteinuria 
(68 – 350 kDa) (Bergstein, 1999; Stierle et al., 1990). A reduction in reabsorptive 
capacity due to tubular or interstitial alterations results in a loss of low molecular 
weight proteins (Marshall and Williams, 1996). Albuminuria is not only the earliest 
clinical evidence of nephropathy, but has been identified as a renal risk factor in both 
diabetic and non-diabetic subjects (Ruggenenti and Remuzzi, 2006; Shumway and 
Gambert, 2002). Microalbuminuria is seen as a more sensitive marker for glomerular 
disease than proteinuria. Proteinuria is a sign of established kidney damage with a 
direct pathogenetic role in the progression of renal disease and direct nephrotoxicity 
(Remuzzi, 1995; Ruggenenti and Remuzzi, 2006). It has been shown that the degree 
of proteinuria strongly correlates with the rate of progression of renal failure in 
diabetic and non-diabetic renal disease (Newman et al., 2000; Wang et al., 2000). 
Exposure of tubular cells to protein is a crucial step of perpetuating progression 
through activation of tubular epithelial cells and the start of interstitial fibrosis (Klahr, 
1999; Odoni and Ritz, 1999; Wang et al., 2000). Therapeutic interventions that aim to 
decrease proteinuria effectively limit the progression to end-stage renal disease 
(Perico et al., 2005). Insights from studies in animal models will hopefully generate 
novel therapeutic modalities for the limitation of progression (Zoja et al., 2006). 
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2.4 Animal models of glomerulosclerosis 
Diverse animal experimental approaches have been applied for studying the 
pathogenesis of glomerulosclerosis and progression of chronic kidney disease. 
Numerous models have been established in the rat with the aim to mirror the various 
elements of human glomerulosclerosis. But since transgenic technologies have 
become established many of these models have been translated to and new models 
have been developed in the mouse species (Fogo, 2003). The ease of physiologic 
manipulations, including direct micropuncture of the glomerulus or repeated renal 
biopsies from the same animal, had been advantages of rats. Due to their small size 
this is very challenging in mice. But having transgenic technologies at hand, the 
possibility of direct investigation of the impact of overexpressing or deletion of 
specific genes makes the mouse a very attractive model (Anders and Schlondorff, 
2000; Fogo, 2003).  
Generally, glomerulosclerosis models can be separated into three groups, the 
conventional experimental models, spontaneously occurring glomerulosclerosis as 
models, and via gene transfer established models. Overviews are given by Wanke 
(1996) and Anders and Schlöndorff (2000). In the group of conventional experimental 
models the so-called remnant kidney model in which more than 50 % of renal tissue 
is removed is the most commonly used model (Heptinstall, 1992; Lafferty and 
Brenner, 1990). Among the models that spontaneously develop glomerulosclerosis 
obesity and hypertension models must be mentioned. Several strategies of 
transgenic technologies have been used for the establishment of nephrologically 
relevant mouse models, including the overexpression of a transgene or the knock out 
of a specific gene (Anders and Schlondorff, 2000; Fogo, 2003; Zoja et al., 2006). A 
well-characterised murine model of progressive glomerulosclerosis is the growth 
hormone (GH) overexpressing transgenic mouse. An example for a model of 
diabetes-associated kidney changes are transgenic mice expressing a dominant 
negative glucose dependent insulinotropic polypeptide receptor (GIPRdn).  
2.4.1 GH transgenic mice 
Mice transgenic for growth hormone were generated for the first time in 1982 
(Palmiter et al., 1982). Since then, several strains of transgenic mice overexpressing 
heterologous GH genes under the transcriptional control of various regulatory 
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elements have been developed (Brem et al., 1989). The systemic overproduction of 
GH in transgenic mice – either due to ectopic expression of heterologous GH genes 
or to stimulation of endogeneous GH release by expression of a GH-releasing 
hormone transgene – regularly leads to a typical spectrum of renal alterations (Wolf 
and Wanke, 1997). These lesions were first reported in 1988 in MT-hGH (Brem and 
Wanke, 1988) and MT-bGH transgenic mice (Doi et al., 1988) and subsequently 
found in many different lines of GH transgenic mice (Wanke et al., 1991; Wanke et 
al., 1992). 
Transgenic mice overexpressing the bovine growth hormone (bGH) under the 
transcriptional control of the rat phosphoenolpyruvate-carboxykinase-promoter 
(PEPCKbGH), which were used in this study, were first described by McGrane 
(1988). These GH transgenic mice display high serum levels of heterologous GH 
(Wolf et al., 1993). A markedly stimulated overall body growth is the most obvious 
phenotypical effect of high serum levels of GH. From three weeks of age onwards, 
GH transgenic mice display an increased body weight as well as visceromegaly and 
disproportionate skeletal gigantism (Wanke et al., 1992). They also demonstrate a 
typical spectrum of pathomorphological alterations of inner organs, with the kidney 
and liver being predominantly affected (Wanke et al., 1991; 1996). In the mouse 
systemic overexpression of GH leads to a typical spectrum of kidney alterations and 
results in chronic renal failure progressing to end-stage renal disease (Wolf and 
Wanke, 1997). Both, morphological and clinical-chemical findings indicate renal 
failure as the primary cause of shortened lifespan of GH transgenic mice (Wolf et al., 
1993). Initial changes include renal and glomerular hypertrophy. Glomerular 
enlargement, which is overproportional in relation to both kidney and body weight, is 
progressive with age and associated with the development of glomerulosclerotic 
lesions (Wanke et al., 1991; 1992). Hypertrophic changes of glomeruli include 
mesangial extracellular matrix expansion, growth of glomerular capillaries and 
proliferation of endothelial as well as mesangial cells. These findings are associated 
with increased proteinuria as well as a variety of tubulo-interstitial changes (Wanke et 
al., 1993). End-stage renal lesions are characterised by a marked atrophy of 
nephrons, tubulocystic alterations, interstitial fibrosis and diffuse segmental or global 
sclerosis and/or hyalinosis of remnant glomeruli (Wanke et al., 1996; Wanke et al., 
1992). 
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Glomerular lesions, especially mesangial lesions, in GH transgenic mice were found 
to bare strong resemblance to those observed in human diabetic glomerulosclerosis 
(Doi et al., 1988). 
Thus, GH transgenic mice represent a valuable and well characterised model to 
study the pathogenesis of glomerulosclerosis and the mechanisms involved in the 
progression of chronic renal failure. 
2.4.2 GIPRdn transgenic mice 
Transgenic mice expressing a dominant negative glucose dependent insulinotropic 
polypeptide receptor (GIPRdn) were created by Volz (1997). The cDNA of the human 
GIP receptor was mutated in the region, coding for the third intracellular loop, by 
introducing a point mutation at amino acid position 340 (Ala  Glu) and a deletion of 
8 amino acids (position 319 – 326). This sequence of G-protein coupled seven-
transmembrane receptors is essential for signal transduction (Lefkowitz and Caron, 
1988). Studies in stably transfected CHL-cells could show unchanged binding affinity 
of the mutated GIP receptor, but no increase in cAMP levels and thus no induction of 
signal transduction. Therefore, this receptor fulfilled all demands of a dominant 
negative receptor and was then chosen for generating transgenic mice. GIPRdn 
transgenic mice were recently characterised clinically and pathomorphologically 
(Herbach, 2002; Herbach et al., 2005). They were found to develop severe early 
onset diabetes mellitus, characterised by hyperglycemia, hypoinsulinemia, 
polydipsia, polyuria and hyperphagia. The onset of diabetes mellitus in these mice 
was found to occur between 14 and 21 days of age. Fasting and postprandial blood 
glucose levels were significantly elevated in transgenic mice in comparison to healthy 
control mice, while serum insulin concentrations were significantly lower (18.8-fold in 
male transgenic mice and 6.1-fold in female transgenic mice), demonstrating an 
absolute insulin deficiency. Total volumes of pancreatic islets and beta-cells were 
dramatically reduced due to a disturbed development of the islets. In addition, GIPRdn 
transgenic mice showed a drastically reduced life-span (Herbach, 2002). Studies of 
the kidneys indicate that GIPRdn transgenic mice develop kidney lesions which 
resemble early diabetes-associated kidney alterations of diabetic humans. GIPRdn 
transgenic mice show renal and glomerular hypertrophy. Additionally, glomerular 
lesions include mesangial expansion with accumulation of extracellular matrix, focal 
segmental glomerular hyalinosis as well as focal adhesions between the glomerular 
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tuft and the capsule of Bowman. Tubulo-interstial lesions include tubular atrophy, 
interstitial fibrosis and signs of proteinuria (Herbach, 2002; Herbach et al., 2003; 
Schairer, 2006). 
In conclusion, GIPRdn transgenic mice are a valuable model for studying diabetes- 
associated kidney lesions. 
2.5 Proteomics 
The proteome is defined as the set of all expressed proteins in a cell, tissue or 
organism (Pennington et al., 1997) and proteomics can be defined as the systematic 
analysis of this set of proteins for their identity, quantity and function (Peng and Gygi, 
2001). Quantitative alterations are addressed in differential proteomic analyses. 
Characteristics and behavior of a biological system are to a high extent modulated by 
biochemical processes on the protein level. The concentration of individual proteins 
in cells or biological fluids is mainly the result of four very complex processes: 
(i) protein synthesis, (ii) protein processing, (iii) protein secretion, and (iv) protein 
degradation (Frohlich et al., 2006). As a consequence, systematic quantitative 
predictions of protein populations are impossible from genomic or transcriptional 
data. Therefore, studies on the proteome level have become an indespensible 
approach in the field of medicine, biochemistry, animal health and agricultural 
sciences (Frohlich et al., 2006; Gygi et al., 2000).  
One of the most important technologies used for proteomics is the two-dimensional 
gel electrophoresis (2DE), which was introduced by O’Farrell and Klose in 1975 
(Klose, 1975; O'Farrell, 1975). Proteins are separated in the first dimension by their 
isoelectric point and by their molecular weight in the second dimension.  
Concerning protein identification great advances could be achieved by two ionisation 
techniques in mass spectrometry, the matrix assisted laser desorption ionisation 
(MALDI) developed by Koichi Tanaka in 1985 (Tanaka et al., 1988) and the 
electrospray ionisation (ESI) developed by John B. Fenn in 1988 (Mora et al., 2000). 
Both researchers were awarded the 2002 Nobel Prize in chemistry and their 
techniques are routinely used since the end of the 1990s. The overall growth of 
proteomics has increased dramatically over the last few years and the use of 
proteomic tools in renal research has been roughly proportional to it (Janech et al., 
2007).  
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2.5.1 2D-gel electrophoresis 
The two-dimensional polyacrylamide gel electophoresis (2DE) is a powerful and 
commonly used strategy in proteomic analyses. It enables the separation of complex 
protein mixtures according to their isoelectric point in the first and according to their 
molecular weight in the second dimension. Routinely, about 2000 different proteins 
can be separated in a single gel experiment. Its resolution and separation power is 
unreached even today, and therefore 2DE still represents a state-of-the-art technique 
(Gorg et al., 2004). In a 2D-gel specific information about a protein spot is available 
(isoelectric point and molecular weight), which can later be used to validate mass 
spectrometry identifications (Peng and Gygi, 2001). However, there are also some 
limitations of 2DE. Specific groups of proteins are known to be excluded or under-
representated in 2DE. Very large and very small proteins as well as highly acidic or 
basic proteins are difficult to separate. The isoelectric focussing (IEF) step is 
incompatible with ionic detergents, such as sodium dodecyl sulphate (SDS), which 
are required for a full solubilisation of proteins. Very hydrophobic proteins can not 
sufficiently be solubilised and therefore not be detected in a gel. But also some 
solubilised proteins may precipitate due to increasing concentrations during the IEF 
step. This hinders a separation in the second dimension (Lilley and Friedman, 2004). 
One of the challenges in identifiying proteins in a complex proteome, such as human 
or animal proteome, is the presence of proteins in wide dynamic concentration 
ranges. Differences in the concentration of proteins in a cell may be over thousands 
to a million times. Hence, a large percentage of the expressed proteins are low 
abundant, for example about 80 % of the whole proteome in yeast, and might not be 
detected without pre fractionation or enrichment (Ahmed and Rice, 2005; Pedersen 
et al., 2003). 
Following electrophoretic separation, staining of proteins is necessary for detection 
and quantification. Three principal staining techniques are commonly used, which 
differ in their sensitivity and linear dynamic range: Coomassie staining, silver 
staining, and fluorescent SYPRO stains (Gade et al., 2003). Coomassie is regarded 
as a less sensitive stain. Silver staining is a very sensitive stain, but it does not allow 
reliable quantification (Gorg et al., 2004). Both staining methods have a limited 
dynamic range of only one to two orders of magnitude. Fluorescent SYPRO stains, in 
particular SYPRO Ruby, are popular, because of the easy staining procedure, high 
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sensitivity and a theoretical linear dynamic range of about four orders of magnitude 
(Nishihara and Champion, 2002). All of these non-covalent staining techniques have 
in common that protein staining is performed after electrophoretic separation. In 
contrast, the 2D difference gel electrophoresis (2D-DIGE) is carried out by a covalent 
labelling of protein samples with different fluorescent dyes prior to the 
electrophoresis, enabling different samples to be co-separated on one gel. 2D-DIGE 
is improving the reproducibility and reliability of differential protein expression 
analysis between samples, while sensitivity and dynamic range are comparable to 
SYPRO stains (Alban et al., 2003; Gade et al., 2003).  
2.5.1.1 Two-dimensional difference gel electrophoresis 
The two-dimensional difference gel electrophoresis (2D-DIGE) was developed by 
Ünlü and colleagues and is an advancement of the classic 2DE (Unlu et al., 1997). It 
allows an improved quantitative analysis of a complex protein mixture. Up to three 
samples are labelled prior to IEF with different fluorescent CyDyes and afterwards 
run on the same 2D-gel under identical conditions. Due to individual excitation and 
emission wavelengths of the CyDyes three different images representing three 
different samples can be obtained from a single 2D-gel. There are two labelling 
techniques available, minimal and saturation labelling. Using minimal labelling the 
CyDyes are covalently bound to the ε-amino groups of lysine of the proteins. The 
amount of the added dye ensures that only 1 – 2 % of the available lysines are 
labelled, i.e. only a fraction of the molecules of an individual protein species is 
labelled at all. A so-called internal pooled standard (IPS) consists of aliquots of all 
samples analysed within a study. The IPS is used to normalize protein abundance 
measurements of each spot across multiple gels in an experiment (Alban et al., 
2003). It is run on each gel and represents the average of all the samples being 
analyzed and ensures all proteins present in the samples are represented. For 
example, in one gel a transgenic and a wild-type sample (labelled with Cy3 and Cy5) 
plus the IPS (labelled with Cy2) are run together. Therefore, qualitative and 
quantitative comparison between the gels is improved and gel to gel variations are 
compensated (Gade et al., 2003). The number of gels in an experiment can be 
reduced by at least a factor of two because two different samples can be run in one 
gel. Moreover, covalent labelling allows a better quantification of spot abundancies. A 
further technique, referred to as “saturation labelling” targets all of the present 
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cysteine residues, thereby allowing the detection of very low protein amounts, i.e. 
approximately 2 µg/image. This technique is especially suitable for the analysis of 
scarce samples (Greengauz-Roberts et al., 2005; Shaw et al., 2003). The general 
workflow of a 2D-DIGE experiment used in this study mainly consists of four steps: 
Labelling and mixing of the protein samples, 2D-gelelectrophoresis and subsequent 
acquisition of the scanned images, software-assisted differential image analysis 
including quantitation and finally identification of the proteins of interest by mass 
spectrometry. 
2.5.2 Mass spectrometry (MS) 
From the two soft ionisation techniques mentioned in chapter 2.5 (MALDI and ESI) 
MALDI analysis is commonly performed to identify proteins in 2D-gel spots. MS-
analysis of proteins is typically performed on the level of peptides, because the m/z-
resolution reached with a mass spectrometer (about 4000 Da), is insufficient for an 
exact discrimination of whole proteins (Lottspeich, 2006). After a tryptic digest of the 
proteins, the analyte is spotted onto a MALDI plate together with a so-called matrix. 
The matrix used in the present study was α-cyano-4-hydroxycinnamic acid, enabling 
the ionization of a peptide by a number of laser impulses. Pulsed laser radiation is 
primarily absorbed by the matrix and then causes desorption and ionisation of the 
analyte.  
In cases where the sample consists of a single protein, a very simple and fast 
strategy called peptide mass fingerprinting (PMF) (Henzel et al., 1993; 2003) is 
frequently applied. The technique is based on exact measurement of the peptide 
masses, followed by a comparison of these values with theoretical peptide masses in 
protein databases. The mass to charge ratio (m/z value) is in many cases not unique 
for a peptide, and therefore per se usually not sufficient for an unambiguous peptide 
or protein identification. The PMF method therefore depends on the assumption that 
all or at least the majority of peptide fragments are derived from a single protein 
species, thereby identifying the protein on the basis of several peptide masses. 
Tandem mass spectrometry or MS/MS is performed to generate additional 
information on the peptide ions and thereby complement the yield of protein 
identifications achieved by PMF analysis alone. In the first MS step the mass of the 
intact peptide, the so called precursor ion, is determined from the PMF spectrum. For 
the second MS step these precursor ions are isolated from all other peptide ions in 
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the instrument and dissociated into fragments. Peptide ions disintegrate under 
suitable energetic conditions at the peptide bonds in a rather controlled manner, 
leading to a set of C-terminally (y-ions) and N-terminally (b-ions) shortened peptide 
ions which give rise to sequence specific MS/MS spectra (Frohlich and Arnold, 
2006). The most common fragmentation technique for peptide ions is the collision 
induced dissociation (CID) (Hayes and Gross, 1990; McLuckey, 1992) where peptide 
ions collide with inert gas atoms or molecules (He, Ar, N2, etc.). The MS/MS spectra 
obtained are then correlated with theoretical MS/MS spectra calculated from 
sequence databases. The sequence of the database peptide with the best correlation 
to the experimental spectrum serves as ‘‘sequence tag’’ for the identification of the 
corresponding protein.  
As an alternative method to 2D gel separation LC-MS/MS analysis can be performed. 
Here liquid chromatography is directly coupled to a mass spectrometer, frequently 
using ESI as ionisation method. Peptide mixtures are first concentrated and 
separated by a reversed phase chromatography and the eluate is directly 
administered to the mass spectrometer (Frohlich and Arnold, 2006). During ESI 
ionisation, the liquid sample flows through a thin needle, and by application of high 
voltage the small droplets are charged and a very fine spray is generated. During the 
passage from the needle to the MS instrument the solvent is evaporated and the 
density of the charges within the droplets rises, causing a so called ‘‘Coulomb 
explosion’’, which results in charged analyte molecules. In cases of peptides these 
ions are commonly multiply charged. Peptide ions of interest are analysed by MS/MS 
analysis. In contrast to 2DE, with this method hydrophobic proteins and proteins with 
isoelectric point (pI) <3 or >10 can also be identified. 
2.5.3 Proteomics in nephrology 
Currently renal and urinary proteomics are performed to better understand renal 
physiology as well as to explore the complexity of disease mechanisms and renal 
pathophysiology (Thongboonkerd and Malasit, 2005). Renal proteomics is a rapidly 
growing field. Proteomic techniques have been used to examine the protein 
expression in the entire kidney or of isolated renal structures as well as to compare 
protein expression between different regions of the kidney (Janech et al., 2007). 
One approach has been to create 2D proteome maps, that could be used as a 
reference for the same type of cell, tissue or sample for further studies, in which 
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additional mass spectrometry analysis would not be required, because protein spots 
on the gel had already been identified (Thongboonkerd, 2004). This must be seen 
from a critical point of view. Regarding the difficulties existing in every laboratory to 
generate positionally identical 2D gels, it is very unlikely that this method can be 
successful (Tonge et al., 2001). Even if one could refer to a spot with a presumably 
identical position, there wouldn’t be a proof whether the formerly identified protein in 
the spot were identical as well. Due to comigration of proteins with the same pI and 
molecular mass in a 2D gel, the presence of several proteins in one spot is not 
unusual. Therefore, it can’t be known just from the position in the gel which protein is 
present in the spot and eventually responsible for differential abundancies (Peng and 
Gygi, 2001). Nevertheless, these qualitative proteome maps can be used to get an 
overview which proteins may be present in a certain tissue or cell. 
A number of qualitative maps of renal protein expression have already been created. 
A first 2D-gel based proteome map of human kidney cortex was established in 1997 
in the SWISS-2DPAGE database (Sarto et al., 1997). With the accessibility of mass 
spectrometric protein identification this list has recently been expanded (Magni et al., 
2005). Proteins from rat kidney cortex and medulla have been compared in two 
studies. Differences between the cytosolic fractions of cortex and medulla could be 
shown and in addition maps of cortical and medullary proteomes were established 
(Witzmann et al., 1998). A map of cortical and medullary proteins using whole cell 
lysates instead of cytosolic fractions has been published in 2002 (Arthur et al., 2002). 
These authors could also identify proteins with differential abundance between cortex 
and medulla. In another study proteome maps of several bovine tissues including the 
kidney could be created (D'Ambrosio et al., 2005). Concerning murine tissue, a 2D-
gel based proteome map of kidneys from FVB mice has been established 
(Thongboonkerd et al., 2004). In this context it must be mentioned, that identical lysis 
and experimental conditions are crucial for the creation of identical 2D-gels. Kidneys 
of different mouse strains can look completely different as noticed by the same group 
in a later study (Thongboonkerd et al., 2006).  
Comparison of protein abundances between different renal compartments or isolated 
structures as well as diseased versus healthy or transgenic animal models versus 
their wild-type controls is a powerful tool of proteomic analysis. Based on the results 
of these holistic approaches the formulation of new hypotheses may become 
possible which could be subject to further studies. An example is a comparative 
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proteomic analysis of kidneys from rats that had been exposed to episodic hypoxia 
(EH) (Thongboonkerd et al., 2002a). After 30 days of EH seven proteins were found 
to be differentially expressed in the kidney, revealing alterations in the renal kallikrein 
pathway. This led to the hypothesis that EH-induced hypertension would be at least 
in part a result from altered regulation of the renal kallikrein system. Most recently, 
changes in the expression of renal proteins associated with hypokalemic 
nephropathy induced by a K+-depleted diet have been demonstrated in mice 
(Thongboonkerd et al., 2006). The identified differentially abundant proteins were 
mainly metabolic enzymes, signalling proteins and cytoskeletal proteins. In another 
study the renal proteome of a transgenic mouse model, which displays 
characteristics of type 1 diabetic nephropathy, with that of non-diabetic FVB mice 
was compared (Thongboonkerd et al., 2004; 2005). Initially, the focus was laid on 
coordinated changes of the monocyte/neutrophil elastase inhibitor (MNEI, increased) 
and elastase IIIB (decreased). An increased tubulointerstitial deposition of elastin as 
a hypothesized result of these changes could be confirmed by immunhistochemistry 
(Thongboonkerd et al., 2004). A second focus was laid on the protein with the 
greatest difference in abundance, the calcium-binding protein calbindin-D28k 
(Thongboonkerd et al., 2005). Increased expression in the kidneys of diabetic mice 
could be confirmed by Western blot analysis. Localization of increased expression of 
calbindin-D28k in tubular epithelial cells could be demonstrated by applying 
immunhistochemistry. The authors suggest that these results may indicate a 
compensatory mechanism for normalisation in tubular calcium reabsorption in 
diabetes.  
In a very recent study 2DE combined with mass spectrometry was used to identify 
changes in protein expression patterns in the renal cortex of the db/db mouse, an 
animal model of type 2 diabetes (Tilton et al., 2007). Numerous diabetes-
dysregulated proteins which modulate metabolism, catabolism, and biosynthesis 
were identified, including a high percentage of mitochondrial proteins. Another 
example for studying changes in proteomes in genetic models of diseases has been 
published recently (Valkova et al., 2005). The renal proteomes of jck mice, a model 
for autosomal recessive polycystic kidney disease, were compared to those of their 
wild-type littermates. An increase in abundance of three proteins, namely galectin-1, 
sorcin, and vimentin, could be shown in the polycystic kidneys. A relation of these 
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differences to the signalling and structural processes in the primary cilium of renal 
epithelial cells was proposed (Valkova et al., 2005).  
Proteomic analyses of protein changes in the entire kidney give a good overview, but 
may not reveal specific processes in certain intrarenal structures. Subproteome 
analyses of these structures (e.g. glomeruli, tubular system, collecting duct) may be 
the method of choice to get a deeper insight in physiological as well as 
pathophysiological processes.  
Proximal tubules play a major role in phosphorus homeostasis. Therefore, one 
approach examined the effect of dietary phosphorus restriction on protein expression 
in rat renal proximal tubules by 2DE (Cheung et al., 2002). Six differentially abundant 
proteins could be found and a general decrease in the number of protein species 
expressed in samples with phosphate restricted diet was observed. In a very recent 
study the adaptive responses of rat renal proximal tubules to metabolic acidosis were 
analysed by applying the 2D-DIGE technique (Curthoys et al., 2007). Well-
characterised adaptive responses in glutaminase, glutamate dehydrogenase, and 
phosphoenolpyruvate carboxykinase could be confirmed. Additionally, previously 
unrecognised adaptive response proteins that differed in their abundance were 
found. 
Some studies focused on the inner medullary collecting duct (IMCD), in which the 
final urine concentration takes place. It is involved as major site in vasopressin-
mediated water and urea reabsorption (Janech et al., 2007). A standardised 
approach for isolation of native renal IMCD cells from rat kidneys was developed and 
its applicability for proteomic analysis was demonstrated in 2004 (Hoffert et al., 
2004). A differential analysis using 2D-DIGE without internal standardization revealed 
50 proteins that showed an increased abundance in the IMCD cells compared to 
non-IMCD cells, including enzymes, structural proteins, and signalling intermediates, 
as well as 35 proteins, being decreased in their abundance in IMCD cells compared 
to non-IMCD cells. The actions of vasopressin in the IMCD of the Brattleboro rat, 
which lacks endogeneous vasopressin, were also investigated by 2D-DIGE analysis 
without internal standardization (van Balkom et al., 2004). The authors could show 
differences in protein expression in vasopressin treated rats compared to non-treated 
animals. Some of the changes were confirmed by immunoblot analysis. In their 
results the authors see a role for vasopressin in the coordinate regulation of several 
determinants of nitric oxide levels and of proteins potentially involved in escape of the 
Literature review 18
antidiuretic action of vasopressin (“vasopressin escape”). Another study could reveal 
a protein regulatory network activated in vasopressin escape by applying both 
proteomics and pathways analysis (Hoorn et al., 2005). This approach enabled the 
identification of differentially expressed, mostly high-abundant proteins by DIGE. 
These proteins were taken for pathway analysis and additionally, the identification of 
relatively low-abundant proteins not detected in the 2D-DIGE analysis could be 
achieved. The investigators could reveal a “dominant regulatory protein network” in 
IMCD cells altered in association with vasopressin escape. 
2.5.3.2 Urinary proteomics 
Urinary proteomics is becoming an important field in nephrology. Urine samples, 
especially from humans, are easy to obtain and no invasive methods like a biopsy is 
needed. A better understanding of tubular and glomerular responses to physiological 
as well as to pathophysiological stimuli can be achieved by examining changes in 
urinary protein excretion (Thongboonkerd and Malasit, 2005). Like in the other 
applications of renal proteomics, several proteome maps of normal human urine 
have been created with gel-based (Bueler et al., 1995; Marshall and Williams, 1996; 
Oh et al., 2004; Thongboonkerd et al., 2002b) or gel-free (Adachi et al., 2006; Heine 
et al., 1997; Spahr et al., 2001; Wittke et al., 2003) approaches. In a recent gel-free 
approach it could be shown that the urinary proteome is unexpectedly complex, 
containing more than 1500 proteins (Adachi et al., 2006). Many studies on different 
physiological as well as pathophysiological situations have been published 
(Gonzalez-Buitrago et al., 2007; Thongboonkerd and Malasit, 2005). Some studies 
focused on changes in urinary proteins during diabetic nephropathy. One approach 
has been to identify specific urinary polypeptide patterns for healthy and diseased 
subjects (Mischak et al., 2004). Using a gel-free method the authors were able to 
differentiate “normal” (urine from healthy subjects), “diabetic” (diabetic and 
normoalbuminuric) and “diabetic renal damage” (diabetic with higher grade 
albuminuria) polypeptide patterns. Another study compared urine from diabetic 
patients with overt proteinuria with control urine by 2D-DIGE analysis (Sharma et al., 
2005). Among the differentially abundant proteins, an increase in alpha 1 antitrypsin 
which was shown to be up-regulated in areas of renal fibrosis by immunostaining 
could be identified. In urine samples of microalbuminuric diabetic patients Jain and 
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colleagues (2005) could show the presence of additional proteins which could be 
used as markers for specific and accurate clinical analysis of diabetic nephropathy. 
2.5.3.3 Glomerular proteomics 
Analyses of renal subproteomes are crucial for a better understanding of kidney 
physiology and pathophysiology, because the kidney consists of many functional 
compartments, and specific protein patterns or changes in abundance can’t be 
distinguished in whole kidney lysates. Especially for glomeruli, which only comprise 
about 2 – 4 % of the whole kidney volume in different species (Artacho-Perula et al., 
1993; Nyengaard and Bendtsen, 1992; Wanke, 1996), such an approach is very 
useful. Despite this fact only a very limited number of studies on glomerular 
proteomics have been performed so far. Like on the whole kidney level the 
establishment of qualitative proteome maps to contribute to further proteomic studies 
has been one aspect of glomerular proteomics. An extensible markup language 
(XML)-based database of human glomeruli, which had been profiled by 2DE, has 
been constructed recently (Yoshida et al., 2005). Glomeruli were purified by a sieving 
method from morphologically unchanged kidney cortices of patients that had to 
undergo nephrectomy due to renal tumors. Cultured podocytes (Ransom et al., 2005) 
and cultured rat mesangial cells (Jiang et al., 2005) also served for the creation of 
2DE based proteome maps. The podocyte proteome has been shown to be rich in 
cytoskeletal proteins and proteins involved in responses to cellular stress (Ransom et 
al., 2005). 
Apart from the database construction only very few 2D-based proteomic studies have 
been performed on isolated glomeruli. Sitek and colleagues (2006) obtained murine 
glomeruli by magnetic isolation and compared the glomerular with the cortical 
proteome using 2D-DIGE saturation labelling. They could show significant 
differences between the expressed proteins in glomeruli and kidney cortex. In 
addition they could demonstrate that only ten human glomeruli (0.5 µg protein) 
picked by laser capture microdissection (LCM) were sufficient to visualize an 
appropriate number of spots on a 2D-gel. Very recently, the glomerular proteome of 
db/db diabetic and db/m non-diabetic mice was compared by 2DE (Barati et al., 
2007). 40 protein spots showed an increased abundance in glomeruli of diabetic 
mice and 32 of them could be identified, suggesting the definition of altered cellular 
redox pathways and advanced glycation end product (AGE) metabolism.  
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As the mesangium plays an important role in glomerulosclerosis, some studies 
focused on 2D-gel based proteomic analyses of cultured mesangial cells. Stress-
induced chaperone proteins could be identified as targets of Akt phosphorylation in 
rat mesangial cells (Barati et al., 2006). The serine-threonine kinase Akt plays a role 
in mesangial cell apoptosis, proliferation and hypertrophy. Cells were treated with 
Akt, and their proteins were afterwards separated by 2D PAGE and identified by 
mass spectrometry. Data suggest that Akt phosphorylation of stress-induced 
chaperones may contribute to mesangial cell proliferation or hypertrophy during 
glomerular diseases. S-Nitrosylation, another post translational modification, had 
been the focus for a proteomic analysis of s-nitrosylated proteins in murine cultured 
mesangial cells (Kuncewicz et al., 2003). Mesangial cells were treated with nitric 
oxide (NO), s-nitrosylated proteins were isolated with a method called “biotin-switch” 
and a 2D-based proteomic analysis followed. Target proteins could be identified by 
MALDI-TOF MS.  
A differential proteomic analysis was performed of control and dexamethasone-
treated cultured murine podocytes treated with dexamethasone in order get an 
insight into the mechanisms of glucocorticoids as primary treatment in the nephrotic 
syndrome (Ransom et al., 2005). Cultured murine podocytes were chosen as target, 
because the podocyte is the most affected kidney cell during the development of 
nephrotic syndrome. Six differentially abundant proteins, three of which were known 
to play roles in protection of cells from injury, were revealed. This led the authors to 
the conclusion that glucocorticoids could have a direct effect on podocytes. 
A different approach in analyses of glomerular proteomics is the use of mass 
spectrometry without 2DE. One study focused on IgA nephropathy (IgAN), which is 
one of the most common glomerular diseases in human beings worldwide. Mass 
spectrometry was applied to analyse the O-glycan structure in IgAN and an 
underglycosylation of IgA1 deposited in glomeruli could be shown, which might play 
an essential role in glomerular deposition of IgA1 molecules (Yasuda et al., 2004).  
In another study, in which mass to charge ratio (m/z) profiles originating from non-
digested proteins of glomeruli isolated by lasercapture microdissection were directly 
acquired by MALDI-TOF mass spectrometry (Xu et al., 2005). Glomeruli were 
obtained from a 5/6 nephrectomy (Nx) rat model of focal segmental 
glomerulosclerosis. A comparison of the different m/z profiles revealed clearly 
distinguishable patterns of glomeruli taken at the day of nephrectomy versus 
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nonsclerotic glomeruli and sclerotic glomeruli. A close relation between patterns of 
sclerotic and nonsclerotic glomeruli suggested an early activation of prosclerotic 
mechanisms in seemingly intact glomeruli. 
Taken together, there is still an enormous need for further studies to reveal 
mechanisms involved in pathophysiology and pathogenesis of glomerulosclerosis. 
Transgenic mouse models and the recent progresses in proteomic technologies are 
excellent tools for the performance of a differential analysis of the glomerular 
proteome. Therefore, the aim of the present study was to identify changes in the 
glomerular proteome of two murine models of nephropathy at early stages of 
glomerulosclerosis by performing a 2D-DIGE based proteomic analysis.  
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3. Animals, material and methods 
3.1 Experimental design 
In order to reveal, whether common characteristic patterns of morphological and 
functional glomerular alterations, displayed by both GIPRdn or GH transgenic mice 
(refer to chapters 2.4.1 and 2.4.2), would result in common changes in the 
abundance of proteins, a quantitative differential proteomic analysis was performed 
on samples of isolated kidney glomeruli. The glomeruli were derived from male GH 
transgenic as well as GIPRdn transgenic mice and their corresponding sex-matched 
wild-type littermate controls. Sample materials were generated from pairs of animals, 
consisting of one transgenic mouse of the respective mouse model and its 
corresponding control animal. For the generation of sample material, both animals of 
one pair were dissected at the same day of age. Investigations were performed at 
two defined stages of early glomerular alterations. These were glomerular 
hypertrophy (stage 1) and glomerular hypertrophy together with a beginning 
albuminuria (stage 2), respectively. GH transgenic and control mice were analysed at 
both stages. GIPRdn transgenic and control mice were only analysed at stage 2. In 
order to enable a meaningful interpretation of the results of the proteomic analysis 
the setting of stringent criteria for the assignment of mice/glomerulus samples to 
stage 1 as well as stage 2 was a crucial prerequisite. Before the glomerulus isolation 
the absence (stage 1) or presence (stage 2) of albuminuria in mice of both mouse 
models had to be determined. This was done by recurrent performance of sodium 
dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE)-based urine 
protein analysis. GH transgenic animals in stage 1 as well as the control animals for 
both groups in stage 1 and 2 had to show an absence of albuminuria. For stage 2 
transgenic mice had to exhibit persistent albuminuria. These results were confirmed 
by Western blot and ELISA experiments. All mice fulfilling these criteria were taken 
for glomerulus isolation. Transgenic animals in stage 1 and 2 had to further display a 
significant increase of the mean glomerular volume as compared to their 
corresponding controls. The mean glomerular volume was estimated by methods of 
quantitative stereology, using histologic samples of kidney tissue that were taken 
before glomerulus isolation. Transgenic mice fulfilling the respective criteria and their 
corresponding controls were selected for differential proteomic analysis. Because the 
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determination of the glomerular hypertrophy was performed after glomerulus 
isolation, more mice were dissected than finally were taken for the proteomic 
analysis. From the glomerulus samples of the selected mice protein was extracted 
and a proteomic analysis was performed using the 2D-DIGE technique. Differentially 
abundant proteins were determined by DeCyder software analysis. Identification of 
the proteins was carried out by applying MALDI-TOF/TOF mass spectrometry 
analysis. The summarised experimental design of the study is displayed in Fig. 3.1. 
Stage 1 Stage 2 Stage 2
co GH tg co GH tg co GIPRdn tg
Determination of body weight, nose-rump-length, kidney
weight
Isolation of glomeruli
2D-DIGE analysis pH 4-7
Identification of proteins by MALDI-TOF/TOF analysis
Determination of the mean glomerular volume
Selection of glomerulus samples for differential proteomic
analysis
Screening for albuminuria: repeated urine protein analysis
by SDS-PAGE, confirmation by Western Blot and ELISA 
experiments
co GH tgvs. GIPRdn tgco vs.
Experimental design
Shared differentially abundant proteins  
Fig. 3.1: Experimental design of the study 
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3.2 Animals 
3.2.1 Breeding, animal husbundary and numbers of mice used for analyses 
The generation of PEPCKbGH transgenic mice is described elsewhere in detail 
(McGrane et al., 1988; Wolf et al., 1993). PEPCKbGH transgenic mice were 
maintained on a NMRI genetic background. They will refered to as GH transgenic 
mice in the following sections. GIPRdn transgenic mice were generated as previously 
described (Herbach, 2002; Herbach et al., 2005; Volz, 1997) and maintained on a 
CD1 genetic background. In both groups male hemizygous transgenic mice were 
mated to female wild-type mice (Charles River Laboratories, Germany) of the 
respective genetic background (NMRI and CD1, respectively). For all investigations 
in this study only male transgenic mice and age-matched wild-type littermate controls 
were used. All mice were maintained under standard (non-barrier) conditions 
(21±1°C, 55±3% relative humidity; 12/12-hours light/dark cycle) and were fed 
standard rodent chow (Altromin C1324, Germany) and tap water ad libitum. All 
animal experiments were performed in accordance with institutionally approved and 
current animal care guidelines. At an age of three weeks, animals were weaned, 
separated according to gender, marked by piercing the ears, and tail tip biopsies 
were taken for genetic analysis. All male mice in a litter were screened for 
albuminuria which included repeated taking of spot urine samples and determination 
of their creatinine concentration. On the whole, 36 litters were screened, 15 in the 
group of GH tg and co mice, representing 37 tg and 40 co mice, and 21 in the group 
of GIPRdn tg and co mice, representing 49 tg and 53 co mice, respectively. All 102 
mice in the group of GIPRdn tg mice and controls were used for determination of 
glucosuria. Glomeruli were isolated from 55 of 77 screened animals in the group of 
GH tg mice and controls (29 tg and 26 co mice) and of 45 of 102 screened animals in 
the group of GIPRdn tg mice and controls (23 tg and 22 co mice), respectively. All 
mice used for glomerulus isolation were also used for the determination of body 
weight, nose-rump length and kidney weight and quantitative stereological analysis 
was performed to determine the mean glomerular volume. Of these mice 20 in the 
group of GH tg mice and controls (5 tg and 5 co in stage 1; 5 tg and 5 co in stage 2) 
and 18 in the group of GIPRdn tg mice and controls (9 tg and 9 co in stage 2) were 
used for the proteomic analysis. Glomerulus isolates from additional two GIPRdn tg 
and two co mice were used to run preparative gels. Only the animals, that were taken 
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for the analytical gels in the proteomic analysis, are included in the results 
presentation. 
3.2.2 PCR-Analysis 
Transgenic mice were identified by polymerase chain reaction (PCR) as previously 
described (Herbach et al., 2005; Hoeflich et al., 2001). For detection of the bGH 
transgene oligonucleotide primers with the following sequence were used: 
5’-GGG ACA GAG ATA CTC CAT CC-3’ sense (bGH #1) 
5’-ATG CGA AGC AGC TCC AAG TC-3’ anti-sense (bGH #2) 
These primers bind to the bGH transgene. The PCR-product of the bGH consists of 
343 base pairs (~pos. 1379-1722 of the bGH-transgene) (Hoeflich et al., 2001). For 
the identification of GIPRdn transgenic mice oligonucleotide primers with the following 
sequence were used:  
5´-ACA GNN TCT NAG GGG CAG ACG NCG GG-3´ sense (Tra1) 
5´-CCA GCA GNC NTA CAT ATC GAA GG-3´ anti-sense (Tra3)  
These primers bind to both the human cDNA of the mutated GIP receptor and the 
endogenous murine GIP receptor. The primers were chosen from areas where the 
known DNA sequence of the human, rat, mouse and hamster GIP receptor is highly 
conserved. The mutated human GIP receptor and the endogenous murine receptor 
can be distinguished in the PCR by their number of base pairs. The PCR product of 
the murine GIP receptor contains about 500 base pairs, whereas the PCR-product of 
the mutated human GIP receptor consists of about 140 base pairs (Herbach et al., 
2005).  
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Fig. 3.2: PCR result of GH transgenic (tg) and control (co) mice. Samples of wild-type control animals 
show no PCR-product (lanes 1-5). GH transgenic animals exhibit a DNA-fragment of 343 base pairs 
(lanes 6-10). M: Fragment size marker (Puc Mix Marker 8, Fermentas, USA). Visible marker bands 
indicate fragment sizes of 1118, 881, 692, 489, 404, 331, 242, 190 and 147 base pairs from top to 
bottom. Ø: spacing line. H2O: no template control. 
 
Fig. 3.3: PCR result of GIPRdn transgenic (tg) and control (co) mice. Samples from wild-type control 
mice show a PCR-product of 500 base pairs (endogeneous GIP receptor, lanes 1, 2, 5-7). GIPRdn 
transgenic mice exhibit a PCR-product of 140 base pairs (mutated GIP receptor, GIPRdn, lanes 3, 4, 8-
10). M: Fragment size marker (Puc Mix Marker 8, Fermentas, USA). Visible marker bands indicate 
fragment sizes of 1118, 881, 692, 489, 404, 331, 242, 190 and 147 base pairs from top to bottom. 
H2O: no template control. 
a) Method 
Tail tip biopsies of approximately 0.4 cm length were taken at weaning and stored at 
-80°C until assayed. For DNA extraction, the tail tip was incubated in 400 μl 
Mastermix over night in a heating block at 55°C. 
Master Mix: 
375 µl Cutting Buffer 
20 µl 20 % SDS 
5 µl Proteinase K (20 mg/ml) 
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Thereafter, undigested components were separated by centrifugation for two minutes 
at 15,000 rpm. The supernatant was poured into another Eppendorf cup, and 400μl 
isopropanol were added to precipitate DNA. The DNA pellet was washed twice with 
900 μl 70% EtOH, the liquid phase was discarded and the DNA pellet was dried at 
room temperature. DNA was suspended in 100 – 200 μl 1*TE buffer, according to the 
size of the pellet when dried. To make sure that the DNA was dissolved completely, it 
was stored at 4°C for at least 24h before proceeding with the PCR. 
19 µl of the Master Mix and 1 µl of the suspended DNA were mixed carefully in PCR-
analysis cups (Eppendorf, Germany), which were then placed in a Mastergradient 
thermocycler (Eppendorf, Germany) and the program was run. DNA of a transgenic 
mouse was used as positive control, DNA of a wild-type control mouse was used as 
negative control, H2O served as quality control. If needed, PCR samples were stored 
at -20°C until further use.  
After amplification, 4 µl of 6* loading dye (MBI Fermentas, Germany) was added to 
each sample. Then the samples were transferred into the sample wells of a 2 % 
agarose gel containing 0.9 µl ethidium bromide per 100 ml (0.1 %), and was 
positioned in an Easy Cast™ gel chamber (PeqLab, Germany) filled with 1*TAE 
running buffer. At the beginning of the row 6 µl PUC Mix Marker # 8 (MBI Fermentas, 
Germany) was placed in a well in order to allow estimation of amplified fragment size. 
Electrophoresis was run for 45 minutes at 90 volt. The amplified products were 
visualised (Eagle Eye II, Stratagene, Germany) under UV light (306 nm) and a digital 
picture was taken to document the result (see Fig. 3.2 and Fig. 3.3). 
b) Materials 
Cutting Buffer: 
2.5 ml 1 M Tris-HCl (pH 7.5; Roth, Germany) 
5.0 ml 0.5 M EDTA (pH 8.0) 
1.0 ml 5 M NaCl (Applichem, Germany) 
250 µl 1 M DTT (Roth, Germany) 
127 µl Spermidine (500 mg/ml; Sigma, Germany) 
Ad 50 ml aqua bidest 
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1*TE buffer: 
10 mM Tris-HCl (pH 8.0) (Roth, Germany) 
1 mM EDTA (Sigma, Germany) 
Proteinase K (Roche, Germany): 20 mg/ml diluted in aqua bidest. 
Primer concentration: 
Tra 1, Tra 3: 10 pmol/µl each (Genzentrum/DNSynthese, Germany) 
bGH 1, bGH 2: 2 µmol/µl each (Genzentrum/DNSynthese, Germany)  
dNTP (Eppendorf, Germany): dATP, dGTP, dTTP, dCTP, 100 mM each 
Master Mix for GH transgenic and control mice: PCR kit (Quiagen, Germany) 
10* buffer 2.00 µl
MgCl2 1.25 µl
Q-solution 4.00 µl
dNTP 1mM 4.00 µl
Primer sense 1.00 µl
Primer antisense 1.00 µl
H2O 5.65 µl
Taq polymerase 0.10 µl
Master Mix for GIPRdn transgenic and control mice: PCR kit (Quiagen, Germany) 
10* buffer 2.00 µl
MgCl2 1.25 µl
Q-solution 4.00 µl
dNTP 1mM 4.00 µl
Primer sense 2.00 µl
Primer antisense 2.00 µl
H2O 3.65 µl
Taq polymerase 0.10 µl
EDTA 0.5 M pH 8.0 
146.1 g EDTA (Sigma, Germany) 
Ad 1000 ml aqua bidest, adjust to pH 8.0 with NaOH (Merck, Germany) 
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50* TAE buffer 
242 g Tris base (Roth, Germany) 
57.1 ml glacial acetic acid (Roth, Germany) 
100 ml 0.5 M EDTA pH 8.0 
Ad 1000 ml aqua bidest. 
1* TAE buffer 
10 ml 50* TAE buffer 
Ad 500 ml with aqua bidest. 
Agarose gel (GIBCO BRL, Germany) 
2 g Agarose / 100 ml 1* TAE buffer, add 9 µl/l ethidium bromide (0.1 %) 
(Merck, Germany) 
Program for DNA amplification of GH transgenic and control mice 
denaturation 94°C 4 min  
denaturation 94°C 1 min 
annealing  58°C 1 min 
extension 72°C 1 min 
35 cycles
final extension 72°C 10 min  
cooling 4°C ∞  
Program for DNA amplification of GIPRdn transgenic and control mice 
denaturation 94°C 4 min  
denaturation 94°C 1 min 
annealing  60°C 1 min 
extension 72°C 2 min 
39 cycles
final extension 72°C 10 min  
cooling 4°C ∞  
 
3.2.3 Detection of glucosuria 
The diabetic phenotype of GIPRdn transgenic mice was reconfirmed by detection of 
glucose in urine samples, using Ratiomed EASY Screen Glucose® sticks (Megro, 
Germany). Spot urine samples were recurrently taken from GIPRdn transgenic mice 
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as well as from their non-transgenic wild-type littermate controls from day 21 on (time 
point of weaning) and investigated until glucosuria was detected in samples of 
GIPRdn transgenic mice. 
3.3 Urine protein analysis 
Repeated urine protein analysis was performed in order to document the absence of 
albuminuria in stage 1 and the onset of albuminuria in stage 2. For stage 1, one urine 
sample was collected on the day before sacrifice. In the group of GH transgenic and 
control mice stage 2 urine samples were collected every two days from 26 days of 
age onwards. In the group of GIPRdn transgenic and control mice urine samples were 
collected weekly from six weeks of age onwards. In both groups 24 hours after the 
first detection of albuminuria a second urine sample was collected and glomeruli 
were isolated from these animals and their corresponding wild-type controls, if 
albuminuria could be confirmed. All urine samples were always taken between four 
and five o’clock in the afternoon and immediately stored at -80°C until assayed. For 
qualitative analysis a sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed. Gels with samples of GIPRdn transgenic mice were 
stained with silver staining and gels with samples of GH transgenic mice with 
Coomassie staining. In order to demonstrate the comparable results, additional SDS-
PAGEs of urine samples taken the day before glomerulus isolation from GH 
transgenic mice and their corresponding controls, which were used for proteomic 
analysis, were run and stained with silver staining. A quantitative analysis of 
albuminuria of urine samples of animals used in the proteomic analysis was 
performed by using an enzyme linked immunosorbent assay (ELISA). 
3.3.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
a) Methods 
Urine creatinine concentration was measured, using an automated analyzer 
technique (Hitachi, Merck, Germany). Urine samples were standardised by dilution 
with sample buffer to a constant creatinine content of 1.5 mg/dl for silver staining and 
3 mg/dl for coomassie staining, respectively. A mouse albumin standard (1 mg/ml; 
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Biotrend, Germany) was diluted 1:50 for silver staining and 1:25 for coomassie 
staining, respectively, in sample buffer. A 12 % separating SDS-polyacrylamide gel 
was casted in a Mini-Protean III gel-casting chamber (Biorad, Germany), overlayed 
with distilled water and allowed to polymerise for 45 minutes. The 5 % stacking gel 
was cast on top of the separation gel and a comb for forming sample wells was 
inserted. The stacking gel was allowed to polymerise for 45 minutes. The comb was 
removed and the gel was placed into a Protean III electrophoresis cell (Biorad, 
Germany), which next was filled with running buffer. Protein was denatured by 
heating the diluted samples and the mouse albumin standard in a thermoblock TB1 
(Biometra, Germany) for 10 min at 96°C. The samples, an additional broad range 
molecular weight standard (Biorad, Germany), and the mouse albumin standard were 
then loaded onto the gel and electrophoresis was run for 60 min at 200 volt. 
Subsequently, either a silver staining or a Coomassie blue staining was performed. 
Silver staining was performed due to a standard protocol (see 10.1 in the 
Attachment). For Coomassie staining the gel was at first stained with the Coomassie 
blue staining solution for 30 min and destained in the Coomassie destaining solution 
for approximately 1.5 hours until clear background. Visible protein bands were 
registered and gels were scanned for documentation (HP Office Jet G55, Germany). 
Finally, gels were dried for long-term storage using the DryEase™ Mini-gel Drying 
System (Invitrogen, Germany) according to the manufacturer’s protocol. 
b) Materials 
Tris/HCl 0.5 M pH 6.8 
6.075 g Tris base (Roth, Germany) 
Ad 100 ml distilled water, adjust pH with 1N HCl (Merck, Germany) 
Tris/HCl 1.5 M pH 8.8 
18.5 g Tris base 
Ad 100 ml distilled water, adjust pH with 1N HCl 
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Sample buffer 
1 ml Distilled water 
0.25 ml Tris/HCl 0.5 M pH 6.8 
0.2 ml Glycerol (Merck, Germany) 
0.4 ml SDS (Sigma, Germany) 10 % 
0.125 ml Bromphenol blue (Sigma, Germany) 0.05 % 
12 % SDS-polyacrylamide gel 
3.5 ml distilled water 
2.5 ml Tris/HCl 1.5 M, pH 8.8 
100 µl SDS 10 % 
4.0 ml Acrylamide 30 % (Roth, Germany) 
50 µl Ammonium persulfate (Biorad, Germany) 10 % 
10 µl Tetraethylethylenediamine TEMED (Roth, Germany) 
5 % SDS-polyacrylamide gel 
6.1 ml distilled water 
2.5 ml Tris/HCl 0.5 M, pH 6.8 
100 µl SDS 10 % 
1.3 ml Acrylamide 30% 
50 µl Ammonium persulfate 10 % 
10 µl Tetraethylethylenediamine TEMED 
Running buffer (stock) 
30.3 g Tris base 
144 g Glycine (Merck, Germany) 
Ad 1 l distilled water 
Running buffer (ready to use) 
40 ml Stock solution 
4 ml SDS 10 % 
Ad 400 ml distilled water 
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Coomassie staining solution 
625 mg Coomassie brilliant blue G250 (Merck, Germany) 
12.5 ml 100 % acetic acid (AppliChem, Germany) 
125 ml 100 % ethanol 
Ad 250 ml distilled water 
Coomassie destaining solution 
17.5 ml 100 % acetic acid 
12.5 ml 100 % ethanol 
Ad 250 ml distilled water 
3.3.2 Western blot analysis 
In order to clarify whether a lane of approximately 67 kDa in the SDS-PAGE reflects 
albumin, Western blot analysis was performed from urine samples of two transgenic 
animals and corresponding controls of both groups investigated in stage 2, according 
to a standard protocol detailed below.  
a) Method 
Materials used are listed below. 
For Western blot analysis, a 12 % SDS polyacrylamide gel was run as described 
above. After electrophoresis, gels were placed on a pre-wetted nitrocellulose 
membrane (Schleicher & Schüll, Germany) between three layers of absorbent paper 
imbibed with buffer, and fiber pads each side, and the Sandwich was set in the gel 
holder cassette. Two cassettes were placed into the electrode module, which was 
then inserted in the buffer lank along with a frozen cooling unit (Mini Trans-Blot Cell, 
Biorad, Germany). After filling the tank with Towbin buffer, the transfer was run over 
night at 30 Volt (Biorad Power PAC 300, Biorad, USA). The membranes were dyed 
with ponceau S solution (Sigma, Germany) to confirm blotting was sucessful. After 
washing in Tris-buffered saline (TBS, pH 8.3), blocking was performed in 1% bovine 
serum albumin (BSA, Sigma, Germany) for one hour to avoid non-specific binding of 
the antibody probe to the membrane. Incubation with rabbit anti-mouse albumin 
antibody probe (Biotrend, Germany; 1:300 in TBS-Tween and 1 % BSA) was 
performed for three hours. The membrane was incubated with horseradish 
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peroxidase conjugated goat anti-rabbit antibody (DAKO Diagnostika, Germany, 
1:1000 in TBS-Tween and 1% BSA) for one hour. After washing three times in TBS-
Tween for ten minutes, immunoreactivity was visualized using 3,3' diaminobenzidine 
tetra hydrochloride dihydrate (Biotrend, Germany) as chromogen. The membranes 
were scanned, dried and stored in a cassette. 
b) Materials 
Towbin buffer 
3.03 g Tris base (Roth, Germany) 
14.4 g Glycine (Merck, Germany) 
200 ml Methanol (Roth, Germany) 
800 ml distilled water 
Storage at 4°C 
Tris buffered saline (TBS) 10* stock solution 
60.6 g Tris base (Roth, Germany) 
87.6 g Sodium chloride (AppliChem, Germany) 
Ad 1 l distilled water, adjust to pH 8.3 with 1N HCl (Merck, Germany) 
Storage at 4°C 
TBS-Tween 
1* TBS (10* TBS stock solution diluted 1:10) 
0.05 % Tween 20 (Sigma, Germany) 
DAB (3,3’ diaminobenzidine tetrahydrochloride dihydrate) 
5 ml DAB (Biotrend, Germany) 
25 ml Tris/HCl 50 mM pH 7.3 
10 µl Hydrogen peroxide, 30 % (Roth, Germany) 
3.3.3 Determination of urinary albumin concentration by ELISA 
In order to confirm the results obtained by SDS-PAGE analysis the concentration of 
urinary albumine in urine samples of all animals used in the proteomic analysis was 
determined by the Mouse Albumin Enzyme Linked Immunosorbent Assay (ELISA) 
Quantitation Kit Bethyl E90-134 (Bethyl, USA). All steps were performed at room 
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temperature. Nunc C bottom immunoplates (Kirkegaard and Perry, USA) were 
coated with 100 µl / well of the provided capture antibody for 60 min. After washing 
for three times with the wash solution 200µl blocking solution was added to each well 
and incubated for 30 min, followed by three washing steps. In the meantime the 
murine albumin standard dilutions were prepared according to manufacturer’s 
protocol with sample diluent. The proper dilution of urine specimens ranged from 
1:60 – 1:6000 (GH tg: 1:300 – 1:6000, GH co: 1:300 - 1:1500, GIPRdn tg: 1:60 – 
1:1600, GIPRdn co: 1:300 – 1:600). Standards, samples and blanks were analysed in 
duplicates. For the first incubation step (60 min), 100 µl of the standard solutions and 
the diluted specimens were added to the coated wells of the ELISA plate. Then, the 
plate was washed for five times by aspiration. In a second incubation step (60 min), 
100 µl of the provided horseradish peroxiase-conjugated detection antibody (diluted 
1:100,000 in sample diluent) were added to each well. Next, the plate was washed as 
described above. Subsequently, the antibody-conjugate that bound to the albumin, 
which was bound to the capture antibody, was detected through a chromogenic 
reaction. Enzyme substrate solution (TMB/H2O2, Kirkegaard and Perry, USA) was 
prepared according to manufacturers recommendations and 100 µl were added to 
each well and incubated for 7 min. To stop the substrate reaction 100 µl of stopping 
solution were added. The colour intensitiy was measured by determining the 
absorbance at 450 nm using a computer-assisted (Magellan; Tecan AG, Germany) 
microplate reader (Sunrise; Tecan AG, Germany). The values of the specimen wells 
were in the linear segment of the calibration curve. Materials used are listed below. 
Materials 
Coating buffer 
0.05 M Carbonate-bicarbonate (Sigma, Germany) 
Adjust to pH 9.6 
Wash solution pH 8.0 
50 mM Tris (Roth, Germany) 
0.14 M NaCl (AppliChem, Germany) 
0.05 % Tween 20 (Roth, Germany) 
Adjust to pH 8.0 
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Blocking solution pH 8.0 
50 mM Tris (Roth, Germany) 
0.14 M NaCl (AppliChem, Germany) 
1 % Bovine serum albumin in Tris buffered saline (Sigma, Germany) 
Adjust to pH 8.0 
Sample diluent pH 8.0 
50 mM Tris (Roth, Germany) 
0.14 M NaCl (AppliChem, Germany) 
1 % Bovine serum albumin in Tris buffered saline (Sigma, Germany) 
0.05 % Tween 20 (Roth, Germany) 
Adjust to pH 8.0 
Stopping solution 
1 M H3PO4 (Roth, Germany) 
3.4 Determination of body weight and nose-rump-length 
All mice were weighed prior to sacrifice. Body weight was determined to the nearest 
0.1 g (Kern KB 5000-1, Kern & Sohn GmbH, Germany). Additionally, the nose-rump-
length was determined.  
3.5 Glomerulus isolation 
Murine glomeruli were isolated using a modified version of a recently published 
method for large scale isolation of glomeruli from murine kidneys perfused with 
spherical superparamegnetic beads (Takemoto et al., 2002). These beads embolize 
the glomerular capillaries. After collagenase treatment of the kidney tissue, glomeruli 
containing beads can be isolated in a magnetic field.  
In order to produce optimal defined sample material glomeruli of only one pair of a 
transgenic mice and its corresponding control were isolated per day between nine 
and eleven o’clock in the morning. Transgenic and control mice were ordered strictly 
random each time. Mice were anesthetised by intraperitoneal injection of ketamine 
(Ketanest®, 80 mg/kg 80 mg/kg, Bayer, Germany) and xylacin (8 mg/kg, Rompun®, 
Bayer, Germany). Approximately 8x107 (a volume of 200 µl, respectively) 
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Dynabeads® M-450 Epoxy (Invitrogen, Germany) were diluted in 40 ml of 38°C warm 
phosphate buffered saline pH 7.4 (PBS) and perfused through the left heart ventricle.  
As perfusion technique had pointed out to be the most important prerequisite for the 
method’s success, a perfusion device developed by Andreas Blutke (German utility 
patent no. DE 202006001542 U1) was used, which allows for uncomplicated 
perfusion of nearly all glomeruli in the adult mouse kidney with sufficient numbers of 
magnetic beads under adjustable pressure conditions (Blutke et al., 2005). Perfusion 
was performed using a perfusion pressure of 70 mm Hg. An incision in the inferior 
vena cava, cranial of the diaphragm provided outflow of the perfusate. The kidneys 
were removed, decapsulated and weighed to the nearest 0.1 mg (BP 61 S, Sartorius 
AG, Germany).  
For histology and morphometric analysis, immunohistochemistry and electron 
microscopy, a sagittal slice of approximately 1 mm thickness was carefully cut from 
the middle of each kidney, using a razor blade. Pieces of 1 mm3 were taken from 
each slice of the renal cortex for electron microscopy and were fixed in 6.25 % 
glutaraldehyde. One and a half kidney slices were taken for histology, fixed by 
immersion in 4% paraformaldehyde (VWR international, Germany), and embedded in 
plastic. The remaining half kidney slice was taken for eventual immunhistochemistry, 
fixed in 4 % paraformaldehyde, and embedded in paraffine.  
The remaining kidney tissue designated for glomerulus isolation was then cut into 
small pieces of approximately 1 mm3 and digested with collagenase (1 mg/ml 
collagenase A, Roche, Germany) in Hanks’ balanced salt solution (Invitrogen, 
Germany) in a 2 ml cup (Eppendorf, Germany) at 37°C for 30 min in a thermoblock 
TB1 (Biometra, Germany) with gentle agitation. The digested tissue was gently 
pressed through a 100-µm cell strainer (BD Biosciences, Germany) in a 50 ml Falcon 
tube (BD Biosciences, Germany), using a flattened pestle and the cell strainer was 
then washed with 6 ml of 4°C cold PBS. The cell suspension was then transferred to 
a 12 ml tube (Techno Plastic Products AG, Switzerland) adding another 3 ml PBS 
and placed into the magnetic field of a strong permanent magnet (BDI MagnetTM Cell 
Separation Magnet, BD Biosciences, Germany) for 5 min. The liquid was removed 
and the isolated tissue containing Dynabeads was resuspended in 9 ml of 4°C PBS 
and placed in the magnetic field for another 5 min. After removing the liquid tissue 
was resuspended in 2 ml PBS and filtered through a new 100-µm cell strainer without 
pressing into a 50 ml tube. The cell strainer was washed with 6 ml of 4°C cold PBS 
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and the suspension was transferred to a 12 ml tube adding 2 ml PBS. From this 
volume an aliquot of 1.5 ml was transferred to a 1.5 ml cup (Eppendorf, Germany) for 
transcriptomic analysis. The remaining volume was placed again into the magnetic 
field for 5 min. After removing the liquid, isolated glomeruli were resuspended in 
1.5 ml PBS, transferred to a 1.5 ml cup and placed into the magnetic field for 2 min. 
Washing steps were repeated for three to four times depending on the grade of purity 
of the isolated glomeruli which was estimated by the control of the wash fluids under 
a photomacroscope (Stemi DV4, Zeiss, Germany). After the last removal of liquid the 
cup with isolated glomeruli was immediately stored at -80°C until further use. During 
the procedure, kidney tissues were kept at 4°C except for the collagenase digestion 
at 37°C. Isolation time, calculated from the animal’s death to the storage of isolated 
glomeruli at -80°C, averaged 100 minutes. 
Phosphate-buffered saline (PBS) (pH 7.4) 
0.25 g Potassium dihydrogen phosphate (AppliChem, Germany) 
8.0 g Sodium chloride (AppliChem, Germany) 
1.46 g Di-sodium hydrogen phosphate dehydrate (AppliChem, Germany) 
Ad 1 l aqua bidest, adjust to pH 7.4 
3.6 Histological technique 
3.6.1 Plastic histology 
For histology and morphometric analysis 1 ½ slices of kidney tissue of each animal 
were fixed by immersion in 4% paraformaldehyde (VWR international, Germany) in 
phosphate buffered saline (PBS pH 7.4) for 24 hours at 8°C and then routinely 
processed for plastic embedding in a Citadel 1000 (Shandon, Germany). In order to 
avoid distortion the kidney slices were fixed with a piece of foam-rubber sponge in 
the tissue-embedding capsules. Subsequently, the kidney slices were processed in a 
hydroxymethylmethacrylate (Fluka Chemie, Germany)/methylmethacrylate (Riedel de 
Haën, Germany) solution at 4°C on a shaker for 18 hours. The kidney slices were 
then shifted into “solution 1”, composed of benzoylperoxide (338 mg; Merck, 
Germany), methylmethacrylate (20 ml), hydroxymethylmethacrylate (60 ml), 
ethyleneglycol monobutylether (16 ml; Merck, Germany), and polyethylene glycol 400 
(2 ml; Merck, Germany). After immersion at 4°C on a shaker for four hours, the 
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kidney slices were placed in plastic cups and embedded using 60 μl of dimethylanilin 
(Merck, Germany) in 40 ml of “solution 1” as starter for polymerisation. Embedding 
cups were immediately placed into a water bath (4°C) and polymerisation took place 
at 4°C over night (Hermanns et al., 1981). Sections of 1.5 μm thickness were cut 
from the casted blocks on a Reichert-Jung 2050 rotary microtome (Cambridge 
Instruments, Germany). The sections were routinely processed and stained with 
Hemalaun-Eosin (H&E) and Periodic Acid Schiff (PAS). Staining procedures are 
listed in the attachment (10.2). 
3.7 Determination of the mean glomerular volume 
The mean glomerular volume was estimated using a model-based method, as 
previously described in detail (Hirose et al., 1982; Wanke, 1996; Weibel and Gomez, 
1962). In this model-based stereological approach, the glomeruli were considered as 
rotation ellipsoids. The mean glomerular area was obtained from planimetric 
measurements of glomerular profile areas. In the calculation, a shape coefficient and 
a size distribution coefficient were considered. The results were corrected for 
embedding shrinkage. The values for the shape and size distribution coefficient as 
well as for the shrinkage correction factor for plastic embedded murine renal tissue 
were taken from Wanke (1996). Morphometric evaluation was carried out on a 
Videoplan® image analysis system (Zeiss-Kontron, Germany) coupled to a light 
microscope (Orhoplan; Leitz, Germany) via a color video camera (CCTV WV-
CD132E; Matsushita, Japan). Images of PAS stained GMA/MMA sections were 
displayed on a color monitor using a Videoplan® image analysis system (Zeiss-
Kontron, Germany). The final magnification on the monitor was 400 x. An object 
micrometer (Zeiss) served for calibration. All glomerular profiles present in the 
sections of one animal (mean 123 ± 25) were sampled according to the unbiased 
counting rule (Horlyck et al., 1986). Glomeruli were sampled by moving the visual 
field along the two lateral lines of a frame displayed on the monitor. Glomeruli 
between the lines or touching the left-hand line were sampled, and those touching 
the right-hand line were excluded to give an unbiased sample. The contours of the 
sampled glomerular profiles were circled with a cursor. The mean glomerular volume 
was calculated using the following equation (Hirose et al., 1982; Wanke, 1996): 
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(glom)(s)v̂ = ßk a (glom)
.
(glom)(s)v̂
ß
k
a
(glom)
: stereologically estimated mean glomerular volume    
(referring to GMA/MMA embedded tissue)
: shape coefficient
: size variation coefficient
: arithmetic mean of areas of glomerular profiles
1.5
 
The values for the shape coefficient (β =1.40) and the size variation coefficient (κ = 
1.04) were taken from Wanke (1996). Results were corrected for embedding 
shrinkage, using the linear tissue shrinkage correction factor (fs = 0.91) for murine 
kidney tissue embedded in GMA/MMA (Wanke, 1996):  
(glom)v =
(glom)v̂ : stereologically estimated mean glomerular volume (prior to embedding)
: linear tissue shrinkage correction favtor for murine kidney tissue               
embedded in GMA/MMA
(glom)(s)v̂ / fs3
fs
3.8 Lysis of glomerulus samples for proteomic analysis 
Cups with isolated glomeruli were centrifuged at 18,000 rcf for 10 min at 4°C in a GS-
15R centrifuge (Beckman, Germany). 80 – 90 µl of cell lysis buffer per 11,000 
glomeruli were added at the wall and spun down for 1 min. Samples were 
homogenized in an iced ultrasonic bath for 5 – 7 min (Sonorex RK 100; Bandelin, 
Germany). The lysates were centrifuged for 2 min at 18,000 g through QIAshredder 
columns (Qiagen, Germany). In order to remove Dynabeads cups were exposed to a 
magnet on ice for 1 min and supernatant was recovered. Protein concentration of 
lysates was assessed by Bradford assay (Bradford, 1976). Lysates were stored at 
-80°C until further use. 
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Cell lysis buffer pH 8.5 
2 M Thiourea (Sigma, Germany) 
7 M Urea (Roth, Germany) 
30 mM Tris (Roth, Germany) 
4 % (w/v) CHAPS (3-[Cholamidopropyl]dimethylammonio)-1-
propanesulfonate) (Sigma, Germany) 
Adjust to pH 8.5 with 25 % HCl (Merck, Germany) 
Bradford reagent 
0.01 % (w/v) Coomassie brilliant blue G-250 (Sigma, Germany) 
5 % (v/v) Ethanol (Roth, Germany) 
10 % (v/v) Phosphoric acid (85 %) (Merck, Germany) 
3.9 Minimal labeling of proteins with fluorescent dyes 
Lyophilised fluorescent dyes (CyDyes) were reconstituted according to the 
manufacturer’s protocol with dimethylformamid (DMF) to give a 1mM solution and 
stored at -20°C. CyDyes were used undiluted from the 1 mM stock solution. Labeling 
reaction for minimal labelling was performed according to the manufacturer’s 
protocol. Labeled samples were stored at -80°C until further processing. 
3.10 2D Difference gel electrophoresis (2D-DIGE) 
3.10.1 Isoelectric focussing (IEF) 
Gel strips (Immobiline™ DryStrips, pH 4-7, 18 cm, GE Healthcare Bio Sciences, 
Germany) were rehydrated in a reswelling tray (GE Healthcare Bio Sciences, 
Germany) in 350 µl rehydration buffer covered with mineral oil (DryStrip Cover Fluid; 
GE Healthcare Bio Sciences, Germany) overnight. Isoelectric focussing was done for 
a total of 44 kVh using anodic cup loading with a Multiphor II device (GE Healthcare 
Bio-Sciences). For the preparative gels, unlabeled protein samples were applied by 
in-gel rehydration and IEF was run for 51 kVh. Focussed gel strips were stored at -
80 °C until further processing. 
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Rehydration buffer 
2M Thiourea (Sigma, Germany) 
7 M Urea (Roth, Germany) 
4 % (w/v) CHAPS (Sigma, Germany) 
13 mM 1,4-dithioerythritol (DTE; Roth, Germany) 
1 % (v/v) Pharmalyte 3-10 (GE Healthcare Bio Sciences, Germany) 
0.8 % (v/v) saturated bromphenol blue solution (Merck, Germany) 
3.10.2 SDS-PAGE 
For SDS-PAGE a separation gel (18 cm x 16 cm x 1 mm) was cast, overlayed with 
ddH2O and allowed to polymerise overnight. The stacking gel (3 cm x 16 cm x 1 mm) 
was cast on top of the separation gel and a comb providing for IPG strip application 
was inserted. The stacking gel was allowed to polymerise for one hour. 
IPG-strips were equilibrated two times for 15 min in 15 ml equilibration buffer 
containing 1 % DTE in the first and 2.5 % iodacetamide + 200 µl saturated 
bromphenol blue solution in the second step on a shaker (100 rpm). Afterwards strips 
were shortened to 14.5 cm, placed onto the stacking gel and fixed with 0.5 % 
agarose (Serva, Germany) in SDS running buffer. Gels were run for 30 min at 30 
mA/gel and 3 hours at 40 mA/gel in SDS running buffer at a temperature of 9 °C 
using a Protein™ II xi device (Bio-Rad, Hercules, CA, USA). The gels in the group of 
GH transgenic mice vs. their controls were processed by the Toplab GmbH 
(Martinsried, Germany), had a dimension of (23 cm x 19.5 cm x 1 mm) and were run 
in an ISO Dalt Tank (Höfer, Germany). 
Separation gel (12 % polyacrylamide) (2 gels) 
26.8 ml ddH2O 
20 ml 1.5 M TrisHCl pH 8.8 (Roth, Germany) 
32 ml Acrylamide / bisacrylamide (37.5:1) (Serva, Germany) 
800 µl SDS 10 % (Serva, Germany) 
400 µl Ammonium persulfate 10 % (Merck, Germany) 
40 µl N,N,N’,N’-Tetramethylethylendiamine (TEMED) (Roth, Germany) 
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Stacking gel (4 % polyacrylamide) (2 gels) 
6.1 ml ddH2O 
2.5 ml 0.5 M TrisHCl pH 6.8 (Roth, Germany) 
1.3 ml Acrylamide / bisacrylamide (37.5:1) (Serva, Germany) 
100 µl SDS 10 % (Serva, Germany) 
50 µl Ammonium persulfate 10 % (Merck, Germany) 
10 µl N,N,N’,N’-Tetramethylethylendiamine (TEMED) (Roth, Germany) 
Equilibration buffer 
6 M Urea (Roth, Germany) 
30 % (v/v) Glycerol (Roth, Germany) 
2 % (w/v) SDS (Serva, Germany) 
50 mM TrisHCl pH 6.8 
SDS running buffer 
25 mM Tris (Roth, Germany) 
192 mM Glycine (Roth, Germany) 
0.1 % (w/v) SDS (Serva, Germany) 
3.10.3 Scanning and analyzing the gels 
Fluorescence scanning of the separated proteins was performed using a Typhoon 
9400 Variable Mode Imager (GE Healthcare Bio Sciences, Germany). Parameters 
were set according to the manual, the photomultiplier tube (PMT) parameters were 
set to 570 V (Cy 3), 560 V (Cy 5), and 800 V (Cy 2), respectively. The group of GH tg 
vs co was scanned using the Ettan™ DIGE Imager (GE Healthcare Bio Sciences, 
Germany) at Toplab GmbH, Martinsried. Exposure was set to 0.500 (Cy3), 0.800 (Cy 
5), and 1.250 (Cy 2), respectively. The resulting images in both groups were 
analyzed with the DeCyder™ Differential Analysis Software v6.5 (GE Health Care 
Bio Sciences, Germany). Pre-matched spot maps created by the software, were 
each inspected and rematched manually to obtain the best possible match quality. 
3.10.4 Staining of gels 
After fluorescence scanning the analytical gels of the group of GIPRdn transgenic and 
corresponding control mice were stained for total protein using Roti®-Blue colloidal 
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coomassie stain. All preparative gels were stained with Roti®-Blue colloidal 
coomassie stain. Staining was performed according to the supplier’s manual. 
3.11 Identification of proteins of interest 
3.11.1 Spot excision and tryptic hydrolysis 
Differentially abundant spots were excised from preparative gels using OMX-S® 
devices (OMX GmbH, Germany) which were used according to the manufacturer’s 
protocol. Briefly a gel spot was selected with the integrated picker, the gel spot was 
centrifuged in the device to crush the matrix into tiny pieces and a volume of 20 µl 
trypsin-digestion buffer (200 ng modified Trypsin sequencing grade porcine 
(Promega, Germany)) was added for the tryptic hydrolysis of proteins (at 50 °C for 
45 min). After tryptic hydrolysis of proteins, peptides were eluted in the same device 
in a clean peptide sample container and dried in a vacuum concentrator (Bachhofer, 
Germany). They were stored at -80°C until further processing. 
3.11.2 Desalting of peptides 
Peptides for subsequent MALDI TOF/TOF mass spectrometry were desalted using 
ZipTipµ-C18® pipette tips (Millipore, Germany). Peptides were reconstituted in 10 µl 
0.5 % trifluoroacetic acid (TFA; Fluka, Germany) and sonicated for three minutes. 
ZipTips were wetted with 50 % acetonitrile (ACN; Merck, Germany), 0.1 % TFA and 
equilibrated with 0.1 % TFA. Peptides were bound to the ZipTip by pipetting up and 
down ten times, followed by two washing steps (first 0.5 % methanol , 0.1% TFA and 
second 0.1 % TFA). Peptides were then directly eluted from the ZipTip with 2 µl 
Matrix solution (5 mg/ml α-cyano-4-hydroxycinnamic acid (Bruker Daltonik, Germany) 
in 50 % acetonitrile, 0.1 % TFA) and spotted on an Opti-TOF™ MALDI target 
(Applied Biosystems, Germany). 
3.11.3 Mass spectrometry and database search 
Peptide mass fingerprint (PMF) spectra were acquired by 1600 laser shots (ND:Yag 
laser, 355 nm) in a mass range between 800 Da and 4500 Da on a 4800 MALDI-
TOF-TOF mass spectrometer (Applied Biosystems). Peak lists were generated using 
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a minimum signal to noise ratio of 10 and prominent human keratin and porcine 
trypsin autolysis peaks were excluded. The ten most intense precursor signals were 
selected for MS/MS fragmentation. MS/MS analysis was performed by 500 laser 
shots and air as collision gas. Peak finding within the MS/MS spectra was performed 
using a signal to noise ratio of 10. Data were transferred to the GPS Explorer 
Software V 3.6 (Applied Biosystems) and searched against the Mus musculus subset 
of the Swissprot database (241365 sequences, date 23112006) using the Mascot 
(Matrix Science Ltd.) search engine with the following parameters: “Enzyme” = 
Trypsin; “Fixed modification” = Carbamidomethyl (C); “Variable modification” = 
Oxidation (M); “Max. missed cleavages” = 1; “Precursor tolerance” = 200 ppm; 
“MS/MS fragment tolerance” = 0.5 Da 
3.11.4 LC-ESI-MS/MS analysis 
LC-ESI-MS/MS analysis was performed with an Ettan MDLC chromatographic device 
coupled to a linear ion trap mass spectrometer. The lyophilized peptides were 
resuspended in 40 µl 0.1 % formic acid (Fluka, Germany) and applied to the device. 
A C18 trap column was utilized for peptide desalting and concentration including a 15 
minute sample application period at a flow rate of 10 µl/min using 0.1 % formic acid. 
Reversed-Phase chromatography to separate the peptides was performed on a C18 
PepMap 100 nano-LC column at a flow rate of 240 nl/min. For mobile phase A, water 
containing 0.1 % formic acid and for mobile phase B, 84 % ACN containing 0.1 % 
formic acid were used. As LC method the following gradient was applied: 
30 min ramp increasing to 30 % mobile phase B, 20 min ram up to 60 % mobile 
phase B, 10 min at 100 % mobile phase B. For application to mass spectrometry, ESI 
ionization was achieved with a needle voltage of 1.4 kV on distal-coated SilicaTips. 
Cycles of one MS scan over the mass range m/z 400-1600 followed by three data 
dependent MS/MS scans were performed in the “dynamic exclusion™ activated” 
mode. Collision energy was set to 35 %. Mascot search of the results includes 
MS/MS data comparing data of the Swiss-Prot database and IPI database for murine 
entries. The search parameters were set as follows: (i) Enzyme: Trypsin; (ii) Variable 
modification: Oxidation (M); (iii) Peptide tolerance: 2 Da; (iv) MS/MS tol.: 0.8 Da; (v) 
Peptide charge: 1+, 2+, 3+; (vi) Instrument: ESI-Trap; (vii) Maximum missed 
cleavages: 2. 
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3.12 Statistical evaluation and data presentation 
Comparisons between the different groups were carried out by performance of two-
tailed Student’s t-tests (type 2), using the MS Excel® software (Microsoft®, USA), 
performed on a personal computer. P values < 0.05 were considered significant. 
Data are presented as means and standard deviation (SD) throughout the study. 
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4. Results 
Differential proteomic analysis was performed on isolated murine glomeruli of two 
different mouse models of glomerulopathy – GH transgenic and GIPRdn transgenic 
mice vs. their wild-type littermate controls – at the defined disease stage of 
glomerular hypertrophy with beginning albuminuria (stage 2). In addition isolated 
glomeruli in the earlier disease stage of glomerular hypertrophy without detectable 
albuminuria (stage 1) were analysed in GH transgenic mice and corresponding 
controls. Only glomerular samples of transgenic mice that fulfilled the stage specific 
criteria and samples of their corresponding age-matched controls were taken for 
proteomic analysis. Therefore, before proteomic analysis a stage- and not age-
specific selection of the samples was made. Urine protein analysis was performed 
regularly in order to determine the presence (stage 2) or absence (stage 1) of 
albuminuria. When this criterium was fulfilled glomeruli were isolated of the 
transgenic and the corresponding control animal. Afterwards the mean glomerular 
volume was determined by quantitative stereology. To be taken for proteomic 
analysis, transgenic mice in both stages had to show glomerular hypertrophy, defined 
as an increase of the mean glomerular volume by at least 30 % as compared to the 
corresponding wild-type littermate control. Subsequently, a 2D-DIGE analysis in the 
pH range 4-7 was performed. 
4.1 Urine protein analysis 
4.1.1 SDS-PAGE 
Urine samples of mice were screened regularly for albuminuria prior to glomerulus 
isolation by SDS-PAGE. On the whole, about 1152 urine samples (391 in the group 
of GH transgenic and control mice and 761 in the group of GIPRdn transgenic and 
control mice, respectively) were taken from 179 animals in both mouse models. With 
these samples about 250 SDS-PAGEs were run for screening purposes. In stage 1 
one urine sample was taken on the day before glomerulus isolation of transgenic (tg) 
and control (co) mice. There was no detectable albumin in the urine of transgenic 
mice as compared to their controls that were taken for proteomic analysis as shown 
in Fig. 4.1. Urine samples of GH tg and wild-type controls (co) stage 2 were screened 
every two days from an age of 26 days onwards and those of GIPRdn tg and co stage 
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2 weekly from an age of six weeks onwards, respectively. 24 hours after the first 
positive result for the presence of albumin a second urine sample which had also to 
be positive was taken one day prior to glomerulus isolation of both GH and GIPRdn tg 
and co mice. All tg animals that were taken for proteomic analysis showed a 
beginning albuminuria as compared to their controls (Fig. 4.2). Intensities of albumin 
bands in urine samples of GH tg animals approximately conformed to those of 
GIPRdn tg mice. In Fig. 4.3 the onset of albuminuria of an exemplary GIPRdn tg mouse 
and its corresponding control as well as an exemplary GH tg mouse and its 
corresponding control is demonstrated: a negative result ten (GIPRdn) / five (GH) 
days prior to glomerulus isolation followed by two positive results for the presence of 
albumin in the urine three and one day prior to glomerulus isolation. Albuminuria was 
confirmed in exemplary GH tg and GIPRdn tg mice as compared to their controls by 
Western blot analysis (see Fig. 4.4). 
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Fig. 4.1: SDS-PAGE of urine samples of GH transgenic (tg) mice in stage 1 and their corresponding 
wild-type controls (co) No albuminuria is detectable in GH transgenic mice as compared to their 
controls on the day before glomerulus isolation. MW molecular weight; M Molecular weight marker; 
Alb Mouse albumin standard 
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Fig. 4.2: SDS-PAGE of urine samples of (a) GH and (b) GIPRdn transgenic (tg) mice in stage 2 and 
their corresponding wild-type controls (co). Transgenic mice of both groups exhibit albuminuria as 
compared to their controls on the day before glomerulus isolation. MW molecular weight; M Molecular 
weight marker, Alb Mouse albumin standard 
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Fig. 4.3: SDS-PAGE demonstrating the onset of albuminuria two days prior to glomerulus isolation. (a) 
GH transgenic (tg) and corresponding wild-type control (co) mouse; (b) GIPRdn tg and corresponding 
co mouse; MW molecular weight; M Molecular weight marker, Alb Mouse albumin standard; day -10,  
-5, -3, -1 urine samples 10, 5, 3, 1 days before glomerulus isolation. 
coco tg tg Alb co co tg tg
GH GIPRdn  
Fig. 4.4: Western blot analysis of urine samples of GH as well as GIPRdn transgenic (tg) and 
corresponding wild-type control (co) mice. Alb: Mouse albumin standard 
4.1.2 Quantification of albuminuria 
Results of the SDS-PAGE analysis give a good impression, whether albuminuria is 
detectable in an urine sample or not, but quantification of the results cannot be made. 
Furthermore, comparisons of urine samples from transgenic vs. those from control 
mice can only be made within one gel and not between different gels. In order to 
confirm and quantify the results obtained by SDS-PAGE, the concentration of 
albumin in the urine of all animals that were taken for proteomic analysis was 
measured by ELISA and the albumin-creatinine-ratio was calculated. In urine 
samples of GH transgenic mice vs. wild-type control mice there was no significant 
difference in the concentration of urine creatinine, whereas in GIPRdn transgenic mice 
the urine creatinine concentration was significantly decreased as compared to their 
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controls (see Fig. 4.5 (a)). In the group of GH transgenic mice in stage 1 there was no 
significant difference in the albumin-creatinine-ratio between transgenic and 
corresponding control animals. In the groups of GH transgenic mice in stage 2 as 
well as GIPRdn transgenic mice in stage 2 the albumin-creatinine-ratio was 
significantly increased in transgenic animals as compared to their controls (see Fig. 
4.5 (b)). 
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Fig. 4.5: Urinary creatinine concentration (a) and albumin-creatinine-ratio (b). (a) GIPRdn transgenic 
(tg) mice exhibit a significantly decreased urine creatinine concentration as compared to their controls 
(co). GH as well as GIPRdn transgenic mice in stage 2 show a significantly increased albumin-
creatinine-ratio as compared to their wild-type controls (co). S1 stage 1, S2 stage 2. Data are 
presented as means ± SD. *p<0.05, **p<0.01 
4.2 Body weight, kidney weight and nose-rump-length 
Right before glomerulus isolation additional parameters (body and kidney weight, 
nose-rump-length) were determined for each animal (see Table 4.1). GH transgenic 
mice in stage 2 showed a significantly increased body weight as compared to their 
controls. Kidney weight and nose-rump-length in GH transgenic mice in stage 1 and 
2 as well as the body weight in GH transgenic animals in stage 1 were increased as 
compared to their control mice, but these differences did not reach statistical 
significance. GIPRdn transgenic mice in stage 2 showed significant changes in all 
analysed parameters as compared to control mice. Body weight and nose-rump-
length were significantly decreased, whereas the kidney weight was significantly 
increased in GIPRdn transgenic animals as compared to their controls. 
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Group  Body weight [g]  Kidney weight [mg]  Nose-rump-length [cm] 
Co (GH, S1)  20 ± 4  339 ± 53  8.7 ± 0.5 
GH tg, S1  22 ± 1  361 ± 15  9.1 ± 0.4 
Co (GH, S2)  26 ± 2  436 ± 53  9.6 ± 0.3 
GH tg, S2  29* ± 2  485 ± 48  10.2 ± 0.5 
Co (GIPRdn, S2)  37 ± 3  635 ± 86  11.0 ± 0.3 
GIPRdn tg, S2  32** ± 3  815** ± 100  10.2** ± 0.4 
Table 4.1: Body weight, kidney weight, nose-rump-length of all mice used for proteomic analysis. 
Differences in of body weight, kidney weight and nose-rump-length of GH transgenic mice in stage 1 
(GH tg, S1) do not reach statistical significance as compared to their controls (Co (GH, S1)). GH 
transgenic mice in stage 2 (GH tg, S2) show a significantly increased body weight as compared to 
their controls (Co (GH, S2)). GIPRdn tg mice in stage 2 (GIPRdn tg, S2) have a significantly reduced 
body weight and nose-rump-length as compared to controls (Co (GIPRdn, S2)). Their kidney weight is 
significantly higher than that of controls. Data are shown as means ±SD; *p<0.05; **p<0.01 
4.3 Mean glomerular volume 
Animals in both stages had to exhibit glomerular hypertrophy, which was defined by a 
significant increase of the mean glomerular volume by at least 30 %. The mean 
glomerular volume was determined by quantitative stereology using plastic sections 
of the kidney slices that had been taken prior to glomerulus isolation in order to select 
the animals for proteomic analysis. The mean glomerular volume (v(Glom), corrected 
for embedding shrinkage) was increased by 58 % on the average in GH transgenic 
animals in stage 1 and by 63 % on the average in stage 2 as compared to their 
control animals. v(Glom) in GIPRdn transgenic mice stage 2 was increased by 42 % as 
compared to their controls as summarized in Fig. 4.6. 
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Fig. 4.6: Mean glomerular volume. S1 stage 1; S2 stage 2; co, wild-type control mice; tg transgenic 
mice. Tg mice show a significant increase in the mean glomerular volume as compared to their 
controls. Data are presented as means ±SD. *p<0.05, **p<0.01 
Examplary cross sections of glomeruli demonstrating glomerular hypertrophy are 
shown in Fig. 4.7.  
All mice that were taken for proteomic analysis exhibited a significant glomerular 
hypertrophy and no albuminuria (GH tg mice in stage 1 vs. corresponding controls) or 
glomerular hypertrophy plus the onset of albuminuria (GH and GIPRdn tg mice in 
stage 2 as compared to their controls). Mice without a sufficient increase in the mean 
glomerular volume did not fulfil the criteria and were excluded from proteomic 
analysis. 
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Fig. 4.7: Glomerular hypertrophy. Glomeruli in histological kidney sections of transgenic (tg) as 
compared to their wild-type control (co) mice demonstrating glomerular hypertrophy; magnetic beads 
are marked by arrows; plastic sections, PAS-staining 
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4.4 Glomerulus isolation 
Glomeruli were isolated from mice with (stage 2) or without albuminuria (stage 1). In 
order to achieve sufficient results concerning quantity and quality a recently 
published method for large scale isolation of glomeruli perfused with spherical 
superparamagnetic beads (refer to 3.5) was modified and optimized for the purpose 
of this study. During the optimization process beads of different size and 
manufacturer were tested for their suitability and the results were very different in 
quantity and quality of the isolated glomeruli. Beads with a diameter of approximately 
1 µm (BeadMAG-55, Chemicell, Germany) lead to very high numbers of isolated 
glomeruli. But beads not only precipitated within the glomerular capillaries (see Fig. 
4.8 (a)), but also in peritubular capillaries. Therefore, a high percentage of non-
glomerular tissue like tubulus fragments was isolated. Other beads (SiMAG-
Oxiran/20), Chemicell, Germany) turned out to have very heterogeneous diameters 
which lead to an obstruction of the afferent arterioles by very large beads and only 
few glomeruli could be isolated (see Fig. 4.8 (b)).  
(a) 
 
(b) 
 
Fig. 4.8: Beads with different diameters. (a) Native sample of a glomerulus perfused with beads with a 
diameter of 1 µm. Precipitated beads are of yellowish colour; magnification 250 x. (b) Histological 
kidney section showing a profile of a glomerulus after perfusion with beads of very heterogeneous 
size. Beads with very large diameter obstruct the vas afferens of the glomerulus preventing beads 
from entering the glomerular capillaries. PAS-staining, magnification 250 x. 
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The best results could be achieved using DynaBeads® M-450 Epoxy with a diameter 
of 4.5 µm (see Fig. 4.9). Out of one murine kidney approximately 10,000 glomeruli 
could be isolated with ~97 % purity. Taking into account that one slice from the 
middle of each kidney was removed prior to and an aliquot for transcriptomic analysis 
during the glomerulus isolation, approximately 11,000 to 13,000 glomeruli per mouse 
could be isolated to be used for the proteomic analysis. 
 
Fig. 4.9: Optimal perfusion of a glomerulus with DynaBeads. Native preparation of a glomerulus 
perfused with DynaBeads® Epoxy. A homogeneous size and distribution of the beads within the 
glomerulus can be observed. Magnification 250 x  
Another critical point in the process of glomerulus isolation turned out to be constant 
and not too high pressure of perfusion. Therefore, perfusion was performed with a 
constant pressure of 70 mm Hg. 
4.5 2D-DIGE analysis of glomerulus preparations 
Glomerulus isolates for proteomic analysis were selected by the criteria glomerular 
hypertrophy (stage 1) and glomerular hypertrophy together with onset of albuminuria 
(stage 2), respectively. Samples of isolated glomeruli were lysed and an average of 
250 µg protein could be extracted from ~12,000 glomeruli isolated per mouse. For 
differential quantitative analysis of the glomerular proteomes of GH transgenic (tg) as 
well as GIPRdn tg mice vs. their corresponding wild-type littermate controls (co) the 
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“2D DIGE minimal labeling” technique was applied. The experimental design of the 
study for one pair – one transgenic mouse and its corresponding wild-type littermate 
control – of each analysed group is outlined in Fig. 4.10. 
GH GIPRdn
Stage (S) 1 Stage (S) 2 Stage (S) 2
co tg co tg co tg
Isolation of glomeruli and tissue lysis
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S2 co
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S2 co + S2 tg
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S1 tg
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S1 co + S1 tg + S2 co + S2 tg
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2D-DIGE analysis pH 4-7  
Fig. 4.10: Experimental design of the study demonstrated for one transgenic mouse and its 
corresponding control of each analysed model. co wild-type control; tg transgenic 
The “internal pooled standards (IPS)”, labeled with Cy 2, consisted of protein aliquots 
from each analysed GH tg mouse and corresponding control and from each analysed 
GIPRdn tg mouse and its corresponding control, respectively. Glomerlus lysates from 
control mice were labelled with Cy 3 and those of transgenic mice with Cy 5. Per 2D-
gel, 50 µg aliquots of glomerular samples from transgenic mice, from corresponding 
control mice and IPS were analysed (150 µg protein in total) on a pH 4-7 gradient. 
Due to relatively low protein amounts in some of the glomerular samples from GIPRdn 
transgenic and control mice 40 µg instead of 50 µg aliquots were analysed (120 µg 
protein in total). After scanning the 2D-DIGE gels, the images were transferred to the 
Results 57
DeCyder software for gel matching, internal standardization and statistical analysis. 
Each group was analysed separately. Spots were considered differentially abundant, 
if they fulfilled the following criteria: (i) spot present in each gel of the analysed group, 
(ii) average abundance ratio of spot volumes ± 1.5, (iii) p-value of the Student’s t-test 
p < 0.01. 
4.5.1 GH transgenic (tg) mice vs. wild-type controls (co) 
In total five biological replicates, representing five GH transgenic mice in stage 1 as 
well as in stage 2 and their corresponding wild-type littermate controls were run. In 
the group of stage 1 one biological replicate was not possible to be analysed. 
Therefore, only four biological replicates were taken for software analysis. After the 
DeCyder software analysis five spots were considered as differentially abundant in 
glomeruli of GH transgenic mice in stage 1 as compared to their controls (see Fig. 
4.11 and Table 4.2), two of which were increased (Spots 1 and 2) in their abundance 
and three were decreased (Spots 3-5) in their abundance. Average abundance ratios 
ranged from – 4.9 (spot 3) to + 2.22 (spot 2). Spot 3 showed the lowest p-value of 
1.9 x 10-4. 22 spots were differentially abundant in the glomeruli of GH transgenic 
mice in stage 2 as compared to controls with average abundance ratios from - 4.25 
(spot 17) up to + 4.17 (spot 14) (Fig. 4.12 and Table 4.3). P-values ranged from 
1.2 x 10-6 (spot 6) to 9.3 x 10-3 (spot 4). Ten spots (spots 1, 2, 6, 7, 10, 13, 14, 15, 19, 
20) were increased in their abundance and 12 spots (spots 3, 4, 5, 8, 9, 11, 12, 16, 
17, 18, 21, 22) were decreased. In Fig. 4.11 and Fig. 4.12 exemplary Cy 3 images 
which represent the samples of the wild-type controls are shown. Differentially 
abundant spots are marked by circles and indicated by numbers. Spot 2 in stage 1 
and spot 14 in stage 2, which represent the same spot in the gels are better visible in 
the corresponding Cy 5 images. Therefore the corresponding areas of both, Cy 3 and 
Cy 5 images are shown in frames on the right of the gel image (Fig. 4.11 and Fig. 4.12).  
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Fig. 4.11: Cy 3 image of a gel in the group of GH transgenic mice in stage 1 vs. their controls in the 
pH 4.3 – 6.8. Differentially abundant protein spots are marked by circles and indicated by numbers 
corresponding to the numbers in Table 4.2. Spot 2 is better visible in the Cy 5 image as shown in the 
lower frame on the right. MW molecular weight. 
Spot DeCyder No. Average Ratio p-value 
1 1186 1.56 0.0053 
2 1289 2.22 0.0062 
3 1641 -4.90 1.9x10-4 
4 1712 -2.49 0.0014 
5 2259 -2.13 0.0054 
    
Table 4.2: Intensity ratios and significance values of the five differentially abundant spots in the group 
of GH transgenic mice in stage 1 vs. their controls. The first column indicates the spots outlined in Fig. 
4.11. The second column shows the corresponding spot number given by the DeCyder software. A 
positive algebraic sign indicates an increase of intensity in the transgenic sample; a negative algebraic 
sign indicates a decrease of intensity. 
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Fig. 4.12: Cy 3 image of a gel in the group of GH transgenic mice in stage 2 vs. their controls in the 
pH 4.2 – 6.8. Differentially abundant protein spots are marked by circles and indicated by numbers 
corresponding to the numbers in Table 4.3. Spot 14 is better visible in the Cy 5 image as shown in the 
lower frame on the right. MW molecular weight. 
Spot DeCyder No. Average Ratio p-value 
1 184 1.51 0.0087 
2 252 1.52 0.0054 
3 371 -1.59 0.0018 
4 372 -1.59 0.0093 
5 375 -1.59 0.0031 
6 448 2.06 1.2x10-6 
7 459 1.99 0.00018 
8 562 -1.59 8.5x10-5 
9 566 -1.51 0.0004 
10 587 1.56 0.001 
11 600 -1.52 0.0013 
12 930 -1.70 0.0014 
13 1097 1.79 0.0019 
14 1168 4.17 0.0011 
15 1183 2.13 0.0011 
16 1235 -1.74 0.00035 
17 1556 -4.25 2.2x10-6 
18 1633 -2.00 0.00053 
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Spot DeCyder No. Average Ratio p-value 
19 1746 1.54 0.0083 
20 2044 1.62 0.0025 
21 2240 -1.56 0.0074 
22 2250 -2.22 0.00023 
    
Table 4.3: Intensity ratios and significance values of the 22 differentially abundant spots in the group 
of GH transgenic mice in stage 2 vs. their controls. The first column indicates the spots outlined in Fig. 
4.12. The second column shows the corresponding spot number given by the DeCyder software. A 
positive algebraic sign indicates an increase of intensity in the transgenic sample; a negative algebraic 
sign indicates a decrease of intensity. 
In order to demonstrate the reproducibility of the analysis, the line charts of the 
identified spots and the corresponding 3D volume plots of the protein spot intensities 
of each biological replicate in the group of GH transgenic mice in stage 2 and their 
controls are shown in Fig. 4.13. The line charts display graphically the altered 
abundance between samples from transgenic and their corresponding control 
animals. The spot abundancies are normalized between the gels on the basis of the 
IPS and are plotted as the abundance in a logarithmic scale (standardized log 
abundance) on the y-axis. The degree of difference in the standardized abundance 
between the two protein spot groups (tg and co) is expressed as the average ratio 
(AR). The line charts are created automatically by the software and the scale on the 
y-axis is not identical for all spots. Normalized abundancies of control samples are 
represented by the left dots, those of transgenic samples on the right. Corresponding 
abundance values from one transgenic mouse and its corresponding control are 
connected by dashed lines. Averages are indicated by crosses and connected by a 
blue line. Dots positioned very close to each other within the protein spot groups and 
parallel dashed lines indicate a very reproducible result and give rise to a low p-
value. For example, in spot 6 (serum albumin) the values for the standardized 
abundance are distributed in a narrower range than in spot 11 (DRP-2), resulting in a 
lower p-value of spot 6 as compared to spot 11. Beneath the line charts, the 
corresponding spots are displayed as 3D-illustrations for each of the five biological 
replicates. In the 3D volume plots the fluorescence intensity of each spot over an 
area is depicted as 3D structur in dependency of the location. X- and y-axis represent 
the spot area of the gel and the z-axis represents the spot intensity of each pixel in 
this ares. Analysed spots are encircled by violet boundaries. These boundaries were 
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created by the algorithm of the software program and could not be influenced by the 
user. Blue and green colour tags show the orientation of the gel, as the coloured 
border indicates the location of the upper edge of the gel. 3D volume plots allow a 
visual comparison of the intensity changes within a sample pair (tg and co sample) 
as well as within the series of the five 2D-DIGE gels. Additionally, they provide 
information about the quality of a spot, e.g. protein spots have a characteristic 
distinguishable appearance as compared for example with peaks caused by dust 
particles on the glass plate, so-called speckles. Protein spots appear as slightly 
rounded peaks that descend fluently into the surrounding area as can be seen e.g. in 
the 3D volume plots of spots 11 (DRP-2) or 16 (Annexin A4). During image analysis 
special care was taken to filter speckles and spots that included speckles, thus 
making quantitation more precise.  
In the subsequent Fig. 4.13 the line charts and 3D volume plots of selected spots from 
the group of GH transgenic mice in stage 2 vs. their controls are shown. These spots 
could be identified (vinculin, filamin-A, serum albumin, dihydropyrimidinase related 
protein 2 (DRP-2), tropomyosin, annexin A4, myosin regulatory light chain (RLC) 2, 
and galectin-1). Some spots contained more than one protein as a consequence of 
comigration and are therefore referred to as multiple IDs. Average abundance ratios 
(AR) were increased for the spots identified as vinculin (+1.51), filamin-a (+1.52), 
serum albumin (+2.06 and +1.99), tropomyosin (+2.13), myosin RLC 2 (+1.54), and 
galectin-1 (+1.62) as well as spot 14 (multiple IDs; +4.17). Average abundance ratios 
were decreased for the spots identified as DRP-2 (-1.59, -1.51, -1.52), annexin A4  
(-1.74) and spots 4 and 5 (multiple IDs; -1.59). 
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Vinculin (1)
AR = 1.51  p = 0.0087
Filamin-A (2)
AR = 1.52  p = 0.0054
Multiple IDs (4)
AR = -1.59  p = 0.0093
Multiple IDs (5)
AR = -1.59  p = 0.0031
co GH tgco GH tg co GH tgco GH tg
Serum albumin (6)
AR = 2.06  p = 1.2x10-6
Serum albumin (7)
AR = 1.99  p = 0.00018
DRP-2 (8)
AR = -1.59  p = 8.5x10-5
DRP-2 (9)
AR = -1.51  p = 0.0004
co GH tgco GH tg co GH tgco GH tg
Results 63
DRP-2 (11)
AR = -1.52  p = 0.0031
Multiple IDs (14)
AR = 4.17  p = 0.0011
Tropomyosin (15)
AR = 2.13  p = 0.0011
Annexin A4 (16)
AR = -1.74  p = 0.00035
co GH tgco GH tg co GH tgco GH tg
Myosin RLC (19)
AR = 1.54  p = 0.0083
Galectin-1 (20)
AR = 1.62  p = 0.0025
co GH tgco GH tg
Fig. 4.13: GH transgenic mice in stage 2 vs. 
their controls: Line charts and 3D volume 
plots of protein spot intensities. For each 
protein, names (spot numbers are enclosed 
in brackets), abundance ratios (AR) and the 
p-values of the Student’s t-test are assigned. 
Individual intensities from each of the six 
replicates are represented as dots (control 
left and transgenic right). Values of 
corresponding samples are connected by 
dashed lines. Averages are indicated by 
crosses and connected by a blue line. For 
each of the five biological replicates, all 3D 
volume plots of the corresponding spots are 
represented below. 
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4.5.2 GIPRdn transgenic (tg) mice vs. wild-type controls (co) 
The first subset of gels with five biological replicates representing five transgenic and 
five wild-type littermate controls had to be excluded from software analysis, because 
the Cy 2 images in all gels were not appropriate due to labelling problems. Therefore, 
eight glomerulus samples from another four pairs of GIPRdn transgenic and control 
mice were taken for a new subset of gels. These samples fulfilled all criteria for 
stage 2, but not all of the pairs were littermates. In total four biological replicates, 
representing four trangenic mice and their corresponding wild-type controls, were 
analysed.  
The internal pooled standard (IPS) of an analysis is represented by the Cy 2 images 
of the gels. Because in each gel an aliquot of the IPS is loaded, the comparison of 
the Cy 2 images allows a judgement about the quality and reproducibility of the 
analysed gels. The Cy 2 images of the four biological replicates in the group of 
GIPRdn transgenic mice in stage 2 and their controls, shown Fig. 4.14, demonstrate 
the good reproducibility of the present analysis. Spot patterns as well as the spot 
intensities look almost identical in each replicate.  
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gel 1 gel 2
gel 3 gel 4
4.3 6.7pH 4.3 6.7pH
4.3 6.7pH 4.3 6.7pH
Fig. 4.14: Cy 2 images representing the IPS of the four biological replicates in the group of GIPRdn 
transgenic mice in stage 2 vs. their controls. 
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After DeCyder software analysis 42 spots fulfilled the criteria mentioned in chapter 
4.5 and were considered as differentially abundant. p-values of the student’s t-test 
ranged from 8.7 x 10-5 (spot 13) to 9.8 x 10-3 (spot 32). 34 spots (spots 1-3, 7, 9, 10, 
12, 14-26, 28-37, 39-42) were increased in the glomeruli of GIPRdn transgenic mice 
in stage 2 as compared to their controls with average abundance ratios from 1.50 
(spot 15) to 5.88 (spot 29). Eight spots (spots 4-6, 8, 11, 13, 27, 38) were decreased 
in the glomeruli of GIPRdn transgenic mice in stage 2 vs. their controls with average 
ratios from -1.51 (spot 5) to -2.90 (spot 38). In Fig. 4.15 a Cy 5 image, representing a 
glomerulus sample from a GIPRdn transgenic animal, is shown and the positions of 
differentially abundant spots are marked by circles and indicated by numbers. The 
intensity ratios and significance values of the respective spots are listed in Table 4.4. 
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Fig. 4.15: Cy 5 image of a gel in the group of GIPRdn transgenic mice in stage 2 vs. their controls in 
the pH 4.3-6.7. Differentially abundant spots are marked by circles and indicated by numbers 
corresponding to the numbers in Table 4.4. MW molecular weight 
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Spot DeCyder No. Average Ratio p-value 
1 467 1.55 0.0083 
2 575 1.80 0.001 
3 740 1.62 0.0063 
4 747 -1.90 0.006 
5 802 -1.51 0.0045 
6 840 -1.64 0.0014 
7 852 1.77 0.0027 
8 937 -1.58 0.0011 
9 969 1.61 0.0031 
10 1045 1.72 0.0094 
11 1057 -1.54 0.0072 
12 1132 1.79 0.0054 
13 1143 -1.85 8.7x10-5 
14 1192 1.67 0.0094 
15 1263 1.50 0.0003 
16 1305 1.53 0.0099 
17 1378 1.63 0.00094 
18 1395 1.64 0.0025 
19 1425 1.77 0.003 
20 1489 1.65 0.0039 
21 1501 1.76 0.0027 
22 1590 1.51 0.0045 
23 1618 1.96 0.0012 
24 1628 1.81 0.0016 
25 1632 1.84 0.0064 
26 1697 1.52 0.0051 
27 1784 -1.58 0.0089 
28 2066 5.05 0.0026 
29 2072 5.88 0.0044 
30 2077 2.98 0.0028 
31 2102 3.00 0.0005 
32 2138 2.42 0.0098 
33 2165 2.56 0.0021 
34 2173 2.32 0.0094 
35 2187 2.20 0.0053 
36 2198 1.74 0.0051 
37 2242 1.54 0.0021 
38 2308 -2.90 0.0001 
39 2382 3.69 0.0064 
40 2387 1.67 0.0018 
41 2519 1.92 0.00012 
42 2528 1.78 0.001 
    
Table 4.4: Intensity ratios and significance values of the 42 differentially abundant spots in the group 
of GIPRdn transgenic mice in stage 2 vs. their controls. The first column indicates the spots outlined in 
Fig. 4.15. The second column shows the corresponding spot number given by the DeCyder software. 
A positive algebraic sign indicates an increase of intensity in the transgenic sample; a negative 
algebraic sign indicates a decrease of intensity. 
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As described in 4.5.1 the line charts and the 3D volume plots of the spot intensities 
show the reproducibility of the analysis. For the group of GIPRdn transgenic mice in 
stage 2 vs. their controls they are shown for identified spots in each of the four 
biological replicates in Fig. 4.16 The average abundance ratios (AR) were increased in 
glomeruli of GIPRdn transgenic mice compared to those of controls in the spots 
identified as sarcosine dehydrogenase (SarDH; +1.55), succinate dehydrogenase 
(DHSA; +1.62), heat shock protein 60 (HSP 60; +1.77), fibrinogen gamma chain 
(FIBG; +1.72), actin (+1.53, + 1.63, + 1.64, +1.67), eukaryotic translation initiation 
factor 3 subunit 1 (eIF-31 alpha; +1.51), tropomyosin (+1.81), Ig kappa light chain 
(KAC; + 5.05), complement C4-B (CO4B; + 2.20), myosin regulatory light chain 2 
(myosin RLC; +1.78) as well as spots 9, 14, 15, 20, 21, 29, 34 and 36 (multiple IDs). 
A decreased average abundance ratio in samples of GIPRdn transgenic mice 
compared to their controls could be detected in the spots identified as 
dihydropyrimidinase related protein 2 (DRP-2; -1.51), bleomycin hydrolase (BLM 
hydrolase; -1.51), annexin A4 (-1.58) as well as spot 11 (multiple IDs). Comparing 
the spot identified as BLM hydrolase with the spot identified as CO4B, differences in 
the line charts can be observed. In the spot identified as BLM hydrolase the values of 
the standardized abundance are very similar within the transgenic as well as within 
the control samples. In contrast, in the spot identified as CO4B especially the 
abundance values of the transgenic samples appear more widely distributed, but are 
nevertheless significantly higher than in the control samples, giving rise to a higher p-
value (p = 5.3 x 10-3) as compared to the spot identified as BLM hydrolase (p = 8.7 x 
10-5). 
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SarDH (1)
AR = 1.55  p = 0.0083
DHSA (3)
AR = 1.62  p = 0.0063
DRP-2 (5)
AR = -1.51  p = 0.0045
HSP-60 (7)
AR = 1.77  p = 0.0027
coco GIPRdn tg coco GIPRdn tgGIPRdn tgGIPRdn tg  
Multiple IDs (9)
AR = 1.61  p = 0.0031
FIBG (10)
AR = 1.72  p = 0.0094
Multiple IDs (11)
AR = -1.54  p = 0.0072
BLM hydrolase (13)
AR = -1.51  p = 8.7x10-5
coco cocoGIPRdn tg GIPRdn tgGIPRdn tgGIPRdn tg  
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Multiple IDs (14)
AR = 1.67  p = 0.0094
Multiple IDs (15)
AR = 1.50  p = 0.0003
Actin (16)
AR = 1.53  p = 0.0099
Actin (17)
AR = 1.63  p = 0.00094
coco cocoGIPRdn tg GIPRdn tgGIPRdn tgGIPRdn tg  
Actin (18)
AR = 1.64  p = 0.0025
Multiple IDs (20)
AR = 1.65  p = 0.0039
Multiple IDs (21)
AR = 1.76  p = 0.0027
eIF-31 alpha (22)
AR = 1.51  p = 0.0045
coco cocoGIPRdn tg GIPRdn tgGIPRdn tgGIPRdn tg  
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Tropomyosin (24)
AR = 1.81  p = 0.0016
Annexin A4 (27)
AR = -1.58  p = 0.0089
KAC (28)
AR = 5.05  p = 0.0026
Multiple IDs (29)
AR = 5.88  p = 0.0044
coco cocoGIPRdn tg GIPRdn tgGIPRdn tgGIPRdn tg  
Multiple IDs (34)
AR = 2.32  p = 0.0094
CO4B (35)
AR = 2.20  p = 0.0053
Multiple IDs (36)
AR = 1.74  p = 0.0051
Actin (40)
AR = 1.67  p = 0.0018
coco cocoGIPRdn tg GIPRdn tgGIPRdn tgGIPRdn tg  
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Myosin RLC (42)
AR = 1.78  p = 0.001
co GIPRdn tg  
Fig. 4.16: GIPRdn transgenic mice in stage 2 vs. their controls: 
Line charts and 3D volume plots of protein spot intensities. For 
each protein, names (spot numbers are enclosed in brackets), 
abundance ratios (AR) and the p-values of the Student’s t-test are 
assigned. Individual intensities from each of the six replicates are 
represented as dots (control left and transgenic right). Values of 
corresponding samples are connected by dashed lines. For each 
of the four biological replicates, all 3D volume plots of the 
corresponding spots are represented below. 
 
4.6 Identification of proteins of differentially abundant proteins 
For identification of the differentially abundant spots, preparative 2D-gels in the pH 
range 4-7 were loaded with a total amount of 500 µg protein from glomerulus lysates. 
In the group of GH transgenic mice vs. their controls a pool of glomerular lysates 
from transgenic and control mice was used for the preparative gel (see Fig. 4.17). In 
the group of GIPRdn transgenic mice vs. their controls one preparative gel was 
prepared with glomerulus samples from transgenic mice and another one with 
glomerulus samples from control mice (see Fig. 4.18). Preparative gels were stained 
for total protein with colloidal Coomassie. Differentially abundant spots were excised 
from the preparative gels and subsequently a tryptic hydrolysis was performed using 
the OMX-S® device. 
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Fig. 4.17: Preparative gel of glomerulus samples from GH transgenic and control mice in pH 4-7. Gel 
contains 500 µg protein. All identified spots are marked by circles and indicated by numbers 
corresponding to the numbers in Table 4.6 MW molecular weight. 
 
Fig. 4.18: Preparative gels of glomerulus samples from control mice (a) and from GIPRdn transgenic 
mice (b) in pH 4-7. Gels contain 500 µg protein each; all identified spots are marked by circles and 
indicated by numbers corresponding to the numbers in Table 4.7. MW molecular weight. 
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14 spots could be excised from the preparative gel of samples from GH tg and co 
mice and 28 from the gels of samples from GIPRdn transgenic and control mice, 
respectively. After tryptic hydrolysis spots were subjected to MALDI-TOF/TOF mass 
spectrometry analysis. Five of the 29 spots from the group of GIPRdn transgenic mice 
in stage 2 vs. their controls were analysed by LC-ESI-MS/MS analysis, because they 
appeared to be very weak spots in the preparative gels. In the groups of GH 
transgenic mice in stage 1 and 2 vs. their controls all 14 excised spots could be 
identified. In the group of GIPRdn transgenic mice in stage 2 vs. their controls 23 of 
24 excised spots could be identified by MALDI-TOF/TOF analysis and 3 of 5 excised 
spots by LC-ESI-MS/MS analysis.  
Peptide mass fingerprint (PMF) spectra of four spots that were unambiguously 
identified by MALDI-TOF/TOF analysis – two in the group of GH transgenic mice 
stage 2 vs. their controls and two in the group of GIPRdn transgenic mice stage 2 vs. 
their controls – are shown in Fig. 4.19 and Fig. 4.20. The PMF spectra of the remaining 
unambiguously identified spots are shown in the attachment. The m/z ratio for the 
precursor ions that are formed during the PMF step is plotted on the x-axis. The 
relative intensities of the peaks in the PMF spectra are plotted on the y-axis. Overall 
the PMF spectra had adequate intensities and for each spot the maximum of 10 
precursor ions were processed by Collision induced dissociation (CID), resulting in 
10 MS/MS spectra per PMF spectrum. 
Fig. 4.21 – Fig. 4.23 show exemplary MS/MS spectra of three precursor ions derived 
from the PMF spectrum of spot 27 in the group of GIPRdn transgenic mice in stage 2 
vs. their controls (Fig. 4.20 (b)) that could be identified as annexin a4. The respective 
precursor ions are indicated by red stars in Fig. 4.20 (d). The peptides identified from 
the three MS/MS spectra could be matched to the sequence of annexin a4. In Fig. 
4.21 the matched b- and y-ions are annotated. Ten of eleven y-ions as well as four of 
eleven b-ions could be positively matched, indicating an unequivocal identification of 
the peptide.  
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Spot 9 in the group of GH tg mice in stage 2 vs. their controls 
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Spot 16 in the group of GH tg mice in stage 2 vs. their controls 
Fig. 4.19: PMF spectra of spots 9 (a) and 16 (b) in the group of GH transgenic mice in stage 2 vs. 
their controls The mass to charge ratio (m/z) is plotted on the x-axis and the peak intensity is plotted 
on the y-axis. 
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Spot 5 in the group of GIPRdn tg mice in stage 2 vs. their controls 
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Spot 27 in the group of GIPRdn tg mice in stage 2 vs. their controls 
Fig. 4.20: PMF spectra of spots 5 (a) and 27 (b) in the group of GIPRdn transgenic mice in stage 2 vs. 
their controls. The mass to charge ratio (m/z) is plotted on the x-axis and the peak intensity is plotted 
on the y-axis. Precursor ions for MS/MS spectra in Fig. 4.21 – Fig. 4.23 are indicated by red stars in 
(b).  
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Fig. 4.21: MS/MS analysis of the 1398.67 precursor ion of the protein annexin A4. (A) Amino acid 
sequence of the 1398.67 precursor ion and schematic representation of all possible b- and y- ions (B) 
MS/MS spectrum of the peptide. The peaks of the measured b- and y-ions are annotated with the 
corresponding m/z-values.  
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Fig. 4.22: MS/MS spectrum of the 1174.59 precursor ion of the protein annexin A4. The detected 
peptide had the amino acid sequence GLGTDDNTLIR. 
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Fig. 4.23: MS/MS spectrum of the 1676.87 precursor ion of the protein annexin A4. The detected 
peptide had the sequence GLGTDEDAIIGILAYR. 
Data from the analysis were searched against the mus musculus subset of the swiss 
prot database using the Mascot search engine. One of the parameters used to 
describe the quality of the database identification is the Mascot Protein Score (also 
called Mowse Score). This score is a measure of significance of a protein 
identification. The absolute value for the minimum score value necessary for a valid 
identification depends on the individual parameters of the search. The protein score 
is based on MS and MS/MS data, and represents a combination of the peptide mass 
fingerprinting (MS data) results and the MS/MS data (Ion Scores). Mascot Ion Scores 
reflect the quality of the MS/MS spectra, and the total Ion Score is based on weighted 
Ion Scores (MS/MS data) for the individual peptides. The Mascot algorithm presents 
this score as a number and a diagram. For valid results of MALDI TOF/TOF MS 
analysis, the score had to be above 54 under the conditions and parameters of this 
study. The area of insignificance is indicated by the green hatched area. Red bars 
indicate a hit in the database. As an example, Fig. 4.24 lists three possibilities for what 
this diagram can look like. This helps to immediately distinguish between 
unambiguously identified, unidentified and ambiguously identified proteins. An 
unambiguously identified protein is represented by only one significant hit, that is 
shown as a red bar outside the green hatched area of insignificance (Fig. 4.24 (a)). 
An ambiguous identification is characterised by two or more significant hits in the 
database, shown as several red bars outside the green hatched area (Fig. 4.24 (b)). 
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If a spot remains unidentified, all red bars are located within the green hatched area 
of insignificance (Fig. 4.24 (c)).  
(a)
(b) (c)  
Fig. 4.24: Possible results of a database search as displayed in the Mascot result. Database hits are 
indicated as red bars. Hits in the green hatched area are not significant. Red bars outside the green 
hatched area indicate significant search results. Unambiguously identified protein (a) (only one 
significant hit), ambiguously identified protein, containing two or more significant hits (b) and the result 
for an unidentified protein spot (c) (no significant hits outside the green hatched area). 
The so-called sequence coverage indicates, how many percent of the amino acid 
sequence of the protein could be covered by positively matched peptides. The 
matched peptides are highlighted in an illustration of the sequence. Fig. 4.25 shows as 
an example the amino acid sequence of the protein annexin a4 identified with a 
protein score of 442 and a sequence coverage of 48 % out of spot 27 in the group of 
GIPRdn transgenic mice in stage 2 vs. their controls, indicating matched peptides by 
red highlighting. This type of sequence representation facilitates a simple 
visualisation of the protein parts identified by MS/MS analysis. 
     1 MEAKGGTVKA ASGFNATEDA QTLRKAMKGL GTDEDAIIGI LAYRNTAQRQ  
    51 EIRSAYKSTI GRDLIEDLKS ELSSNFEQVI LGLMTPTVLY DVQELRRAMK  
   101 GAGTDEGCLI EILASRTPEE IRRINQTYQQ QYGRSLEEDI CSDTSFMFQR  
   151 VLVFLSAAGR DEGNYLDDAL MKQDAQELYE AGEKRWGTDE VKFLSILCSR  
   201 NRNHLLHVFD EYKRISQKDI EQSIKSETSG SFEDALLAIV KCMRSKPSYF  
   251 AERLYKSMKG LGTDDNTLIR VMVSRAEIDM LDIRASFKRL YGKSLYSFIK  
   301 GDTSGDYRKV LLILCGGDD 
Fig. 4.25: Amino acid sequence of the protein annexin a4. Matched peptides are shown in bold red. 
Sequence coverage was 48%. 
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4.6.1 GH transgenic mice vs. their controls 
In the group of GH transgenic mice in stage 1 vs. their controls only one of five 
differentially abundant spots could be identified by MALDI-TOF/TOF analysis, but 
contained a mixture of three different proteins as a consequence of comigration. This 
spot 2 in stage 1 conforms to the spot 14 in stage 2. In stage 2, 11 out of 22 
differentially abundant spots could be unambiguously identified and three were 
identified with an ambiguous result of two or more proteins by MALDI-TOF/TOF 
analysis. Protein scores ranged from 81 up to 867. Among the 11 unambigous 
results were eight unique proteins and five isoforms. Serum albumin was found in 
spots 6 and 7 and dihydropyrimidinase-related protein 2 was found in spots 8, 9, 11. 
The data of all identified spots are listed in Table 4.5 (stage 1) and Table 4.6 (stage 2). 
Spot 15 in stage 2 was identified as tropomyosin, but a definite statement about the 
isoform cannot be made from the database result. 
Mass [Da] pI 
Spot DeCyder No. Protein 
Swiss Prot 
Entry name PS 
SC 
[%] 
Number 
of 
peptides 
identified 
by 
MS/MS 
Data- 
base gel 
Data- 
base gel 
           
2 1289 1) Serum albumin precursor ALBU_MOUSE 230 25 3 70700 38000 5.75 5.68
  2) Guanine nucleotide-binding 
protein subunit beta 4 
CBB4_MOUSE 81 24 0 37965  5.74  
  
3) BTB/POZ domain-
containing protein KCTD12 
KCD12_MOUSE 96 11 0 36155  5.63  
Table 4.5: Most important parameters of the identified spots in the group of GH transgenic mice in 
stage 1 vs. their controls. SC = sequence coverage; PS = Mascot protein score; pI = Isoelectric point. 
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Mass [Da] pI 
Spot DeCyder No. Protein 
Swiss Prot 
Entry name PS 
SC 
[%]
Number 
of 
peptides 
identified 
by 
MS/MS 
Data- 
base gel 
Data- 
base gel 
           
1 184 Vinculin VINC_MOUSE 343 38 1 117083 115000 5.77 5.87
2 252 Filamin-A FLNA_MOUSE 305 17 2 283738 99000 5.68 6.30
4 372 1) Ezrin EZRI_MOUSE 408 39 3 69347 76000 5.83 6.05
  2) Moesin MOES_MOUSE 199 21 3 67708  6.24  
  3) Radixin RADI_MOUSE 182 20 3 68672  5.85  
5 375 1) Ezrin EZRI_MOUSE 716 57 8 69347 76000 5.83 6.15
  2) Moesin MOES_MOUSE 336 27 4 67708  6.24  
  3) Radixin RADI_MOUSE 313 22 5 68672  5.85  
6 448 Serum albumin precursor ALBU_MOUSE 601 50 5 70700 71000 5.75 5.68
7 459 Serum albumin precursor ALBU_MOUSE 384 42 4 70700 71000 5.75 5.62
8 562 Dihydropyrimidinase-related 
protein 2 
DPYL2_MOUSE 570 50 6 62638 63000 5.95 5.97
9 566 Dihydropyrimidinase-related 
protein 2 
DPYL2_MOUSE 633 58 5 62638 62000 5.95 6.10
11 600 Dihydropyrimidinase-related 
protein 2 
DPYL2_MOUSE 867 54 9 62638 63000 5.95 6.02
14 1168 1) Serum albumin precursor ALBU_MOUSE 230 25 3 70700 38000 5.75 5.68
  2) Guanine nucleotide-
binding protein subunit beta 4 
CBB4_MOUSE 81 24 0 37965  5.74  
  3) BTB/POZ domain-
containing protein KCTD12 
KCD12_MOUSE 96 11 0 36155  5.63  
15 1183 Tropomyosin 1 alpha chain * TPM1_MOUSE 199 44 1 32718 37000 4.69 4.50
16 1235 Annexin A4 ANXA4_MOUSE 527 62 6 36121 36000 5.43 5.33
19 1746 Myosin regulatory light chain 
2, smooth muscle isoform 
MLRN_MOUSE 315 63 5 19767 22000 4.80 4.67
20 2044 Galectin-1 LEG1_MOUSE 302 61 4 15067 14000 5.33 4.97
Table 4.6: Most important parameters of the identified spots in the group of GH transgenic mice in 
stage 2 vs. their controls. SC = sequence coverage; PS = Mascot protein score; pI = Isoelectric point. 
* one of three possible isoforms 
4.6.2 GIPRdn transgenic mice in stage 2 vs. their controls 
Of the 42 differentially abundant spots in the group of GIPRdn transgenic mice in 
stage 2 vs. their controls 16 spots could be unambiguously identified and seven 
ambiguously with two or more proteins by MALDI-TOF/TOF MS analysis. Protein 
scores from 58 up to 789 could be observed. The 16 unambiguously identified spots 
corresponded to 13 unique proteins. With LC-ESI-MS/MS analysis three spots could 
be ambiguously identified. The nominal mass and pI were consistent with the 
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observed values in most the spots. The most important parameters of all identified 
spots are listed in Table 4.7. For spot 24 (Tropomyosin) and spots 16, 17, 18, 20 and 
40 (Actin) the database result shows several possible isoforms with different protein 
scores. Taken into account that the result with the lowest protein score is identified 
by the same peptides like those hits with higher scores a definite statement about 
which isoform is exactly present cannot be made by the database results. 
 
Mass [Da] pI 
Spot DeCyder No. Protein 
Swiss Prot 
Entry name PS 
SC 
[%]
Number 
of 
peptides 
identified 
by 
MS/MS 
Data- 
base gel 
Data-
base gel 
           
1 467 Sarcosine dehydrogenase, 
mitochondrial precursor 
SARDH_MOUSE 89 11 0 102644 97000 6.28 6.23 
3 740 Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
precursor 
DHSA_MOUSE 291 27 3 73623 78000 7.06 6.32 
5 802 Dihydropyrimidinase-related 
protein 2 
DPYL2_MOUSE 579 45 8 62638 63000 5.95 6.23 
7 852 60 kDa heat shock protein, 
mitochondrial precursor 
CH60_MOUSE 723 46 7 61088 58000 5.91 5.33 
9 969 1) Lactadherin precursor MFGM_MOUSE 71 15 0 53376 56000 6.10 5.92 
  2) Nidogen-1 precursor SPTB1_MOUSE 67 5 0 139387  5.25  
10 1045 Fibrinogen gamma chain 
precursor 
FIBG_MOUSE 319 32 4 50044 50000 5.54 5.43 
11 1057 1) Heterogeneous nuclear 
ribonucleoprotein H 
HNRH1_MOUSE 287 37 3 49322 51000 5.89 5.92 
  2) Heterogeneous nuclear 
ribonucleoprotein H' 
HNRH2_MOUSE 174 23 2 49322  5.89  
  3) Cell cycle checkpoint 
protein RAD17 
RAD17_MOUSE 70 15 0 77913  5.80  
13 1143 Bleomycin hydrolase BLMH_MOUSE 61 22 0 53104 51000 6.04 6.32 
14 1192 1) Vimentin VIME_MOUSE 789 73 8 53581 45000 5.06 4.71 
  2) Desmin DESM_MOUSE 121 16 1 53391  5.21  
  3) Peripherin PERI_MOUSE 71 16 1 54349  5.40  
15 1263 1) BCKDH E1-alpha ODBA_MOUSE 236 19 5 50624 45000 8.14 6.35 
  2) Elongation factor Tu, 
mitochondrial 
EFTU_MOUSE 234 35 4 49876  7.23  
  3) hnRNP D0 HNRPD_MOUSE 32 5 1 38501  7.62  
16 1305 Actin, cytoplasmic 2 * ACTG_MOUSE 773 56 8 42108 42000 5.31 5.17 
17 1378 Actin, cytoplasmic 2 * ACTG_MOUSE 207 26 2 42108 41000 5.31 5.17 
18 1395 Actin, cytoplasmic 2 * ACTG_MOUSE 600 41 6 42108 41000 5.31 5.03 
20 1489 1) Isocitrate dehydrogenase 
[NAD] subunit alpha, 
mitochondrial precursor 
IDH3A_MOUSE 316 38 3 40069 38000 6.27 5.52 
  2) Actin, cytoplasmic 2 * ACTG_MOUSE 272 26 4 42108  5.31  
21 1501 1) Phosphotriesterase-related 
protein 
PTER_MOUSE 50 10 1 39193 39000 6.18 6.35 
  2) S-Arrestin ARRS_MOUSE 36 2 1 44902  5.57  
22 1590 Eukaryotic translation 
initiation factor 3 subunit 1 
IF31_MOUSE 77 15 1 29582 35000 4.69 4.61 
24 1628 Tropomyosin 1 alpha chain** TPM1_MOUSE 211 35 2 32718 34000 4.69 4.61 
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Mass [Da] pI 
Spot DeCyder No. Protein 
Swiss Prot 
Entry name PS 
SC 
[%]
Number 
of 
peptides 
identified 
by 
MS/MS 
Data- 
base gel 
Data-
base gel 
25 1632 1) PDHE1-B ODPB_MOUSE 62 8 1 39254 35000 6.41 5.45 
  2) Annexin A3 ANXA3_MOUSE 39 8 1 36389  5.33  
  3) SBCAD ACDSB_MOUSE 39 5 1 48300  8.00  
27 1784 Annexin A4 ANXA4_MOUSE 442 48 5 36121 31000 5.43 5.36 
28 2066 Ig kappa chain C region KAC_MOUSE 65 35 1 11942 23000 5.23 6.37 
29 2072 1) Heterogeneous nuclear 
ribonucleoprotein H 
HNRH1_MOUSE 178 14 3 49322 23000 5.89 6.51 
  2) Heterogeneous nuclear 
ribonucleoprotein H' 
HNRH2_MOUSE 177 14 3 49533  5.89  
34 2173 1) Glutathione peroxidase 3 
precursor 
GPX3_MOUSE 241 32 3 25589 22000 8.26 5.66 
  2) Glutathione peroxidase 1 GPX1_MOUSE 58 23 1 25553  6.74  
35 2187 Complement C4-B precursor CO4B_MOUSE 82 8 0 194403 22000 7.54 6.44 
36 2198 1) ATP synthase D chain, 
mitochondrial 
ATP5H_MOUSE 164 35 3 18664 21000 5.52 5.27 
  2) COMM domain-containing 
protein 8 
COMD8_MOUSE 62 10 1 21067  5.38  
40 2387 Actin, cytoplasmic 2 * ACTG_MOUSE 247  4 42052 16000 5.29 5.27 
42 2528 Myosin regulatory light chain 
2, smooth muscle isoform 
MLRN_MOUSE 117 28 2 19767 19000 4.80 4.51 
  
         
Table 4.7: Most important parameters of the identified spots in the group of GIPRdn transgenic mice in 
stage 2 vs. their controls. SC = sequence coverage; PS = Mascot protein score; pI = Isoelectric point; 
italic = spots identified via LC-ESI-MS/MS. * one of six possible isoforms; ** one of three possible 
isoforms 
4.6.3 Proteins with differential abundance in GH transgenic as well as GIPRdn 
transgenic mice in stage 2 vs. their corresponding controls 
Of the eight unique proteins identified in the group of GH transgenic mice in stage 2 
vs. their controls and the 13 unique proteins identified in the group of GIPRdn 
transgenic mice in stage 2 vs their controls an intersection of four identical proteins 
could be build (see Table 4.8). These proteins were consistent with the direction of the 
change in abundance as well as with the approximate level of the abundance ratio. 
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   GH tg vs. co GIPRdn tg vs. co 
Protein   AR Spot No. AR Spot No.
      
Dihydropyrimidinase 
related protein 2  
-1.59 
-1.51 
-1.52 
8 
9 
11 
-1.51 5 
Annexin A4  -1.74 16 -1.58 27 
Myosin regulatory light 
chain 2, smooth muscle 
isoform 
 
1.54 19 1.78 42 
Tropomyosin   2.13 15 1.81 24 
       
Table 4.8: Overlap of identified proteins in the groups of GH transgenic mice and GIPRdn transgenic 
mice in stage 2 vs. their corresponding controls. tg transgenic, co wild-type control; AR abundance 
ratio 
Discussion 85
5. Discussion 
5.1 General aspects 
In the present study a differential proteomic analysis of glomeruli from two different 
murine models of glomerulopathy was performed at defined disease stages. GH 
transgenic as well as GIPRdn transgenic mice develop comparable early functional 
and morphological glomerular alterations. Glomeruli of transgenic mice and 
corresponding age-matched littermate controls were isolated at the stage of 
glomerular hypertrophy together with beginning albuminuria. Additionally, glomeruli of 
GH transgenic and control mice were isolated at the earlier stage of glomerluar 
hypertrophy without albuminuria. For glomerulus isolation a recently published 
method which bases on the perfusion of glomeruli with spherical superparamagnetic 
beads embolizing the glomerular capillaries was modified and optimized for the 
purposes of the present study (Takemoto et al., 2002). Subsequently, a 2D-DIGE 
based proteomic analysis was performed on the isolated glomeruli. This resulted in a 
number of differentially abundant proteins between transgenic and controls in each of 
the analyzed groups. Differentially abundant proteins were identified by MALDI-
TOF/TOF analysis. The overall aim of the study was not only to identify differentially 
abundant proteins within one group, but to build up an intersection of the identified 
proteins between the group of GH transgenic mice in stage 2 and their controls and 
the group of GIPRdn transgenic mice in stage 2 and their controls. This intersection 
represents a common pattern of identical proteins, independent of the transgene 
expression and the different genetic background (NMRI and CD1) of the two 
investigated mouse models. 
5.2 Mouse models and analysed disease stages 
Glomerular hypertrophy is considered to play a major role in the progression of 
chronic renal failure. In the concept of Fogo and Ichikawa it is postulated that 
disease-specific initial pathogenic insults lead to a reduced number of nephrons 
followed by glomerular hypertrophy (Fogo and Ichikawa, 1989; Ichikawa et al., 1991). 
The latter then leads to glomerular damage, further loss of nephrons and feeds the 
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vicious cycle that ends in the chronic renal failure. In primary focal segmental 
glomerulosclerosis and diabetes mellitus associated kidney lesions glomerular 
hypertrophy develops per se without a prior nephron loss. Nevertheless, the exact 
mechanisms of the pathogenesis of glomerulosclerotic alterations are yet to be found 
out. Albuminuria following glomerular hypertrophy is the earliest clinical evidence of 
glomerular damge and has been shown to be a sensitive marker for kidney disease 
as well as a renal risk factor (Ruggenenti and Remuzzi, 2006; Shumway and 
Gambert, 2002). Insights from animal models are still needed to enable an 
intervention at an early time point (Zoja et al., 2006). In order to find out proteins with 
potential relevance in the early steps of glomerulosclerosis development the early 
stage lesions, characterised by glomerular hypertrophy together with albuminuria, 
were chosen for this study. In GH transgenic mice glomerular hypertrophy without 
albuminuria was additionally analysed, because in these mice glomerular 
hypertrophy develops reliably four to five days before the onset of albuminuria. The 
two mouse models in this study were chosen, because they allowed the analysis of 
comparable morphological and functional glomerular lesions due to different reasons 
for their development of nephropathy. GH transgenic mice represent a model for 
progressive glomerulosclerosis (Wanke, 1996). GIPRdn transgenic mice develop 
severe diabetes mellitus and are a model for diabetes associated kidney lesions 
(Herbach, 2002; Herbach et al., 2003; Schairer, 2006). Both models show glomerular 
hypertrophy, albuminuria and glomerulosclerosis. The morphological and functional 
glomerular alterations are comparable, but they begin at totally different time points in 
the two models. In GH transgenic mice glomerular hypertrophy is already detectable 
at about 27 days of age and albuminuria starts about four to five days later. In GIPRdn 
transgenic mice the alterations develop from seven to eight weeks of age onwards. 
Therefore, an intersection of identified differentially abundant proteins between both 
groups is of particular interest. 
In order to obtain reproducible and meaningful results in the proteomic analysis it is 
crucial to use optimally defined sample material. In the present study mice of which 
glomeruli were used for proteomic analysis were carefully selected by stringent 
criteria. These criteria were stage- but not age-specific. This was especially important 
for the selection of glomerular samples from GIPRdn transgenic and control mice, 
because the onset of albuminuria in GIPRdn transgenic mice varies in weeks. Out of 
the high number of screened mice only those were selected for proteomic analysis 
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which demonstrated a significant albuminuria as well as a glomerular hypertrophy as 
compared to their controls. In the stage of albuminuria transgenic mice in both 
models had to show two urine samples, which were taken in an interval of 48 hours, 
with a positive result for albuminuria in order to avoid choosing animals with only a 
transient albuminuria. Because GIPRdn transgenic mice exhibited a severe diabetic 
polyuria, some aspects had to be considered during urine protein analysis to get 
comparable results. For SDS-PAGEs all urine samples were set to an identical 
creatinine concentration. The concentrations of albumin in the urine samples were 
determined by an ELISA experiment. Afterwards the measured albumin 
concentrations were set in relation to the creatinine concentrations and the albumin-
creatinine-ratio was calculated. The comparability of the grade of albuminuria in GH 
transgenic and GIPRdn transgenic mice could be demonstrated by both analyses. 
The presence of glomerular hypertrophy was the prerequisite in both disease stages 
and mouse models. The mean glomerular volume was determined by quantitative 
stereology applying a model-based method frequently used for this purpose (Hirose 
et al., 1982; Wanke, 1996). Only mice that demonstrated an increase in the mean 
glomerular volume by at least 30 % as compared to the corresponding controls were 
chosen for the proteomic analysis. Early glomerular hypertrophy in GH transgenic 
mice is in line with previous results (Fisch, 2004; Wanke, 1996). 
For a further characterisation of the analysed mouse models body and kidney weight 
as well as the nose-rump-length of each animal were determined prior to the process 
of glomerulus isolation. In GIPRdn transgenic and control mice the results are 
consistent with earlier studies on these mice (Herbach, 2002; Herbach et al., 2005). 
GIPRdn transgenic mice had a significantly reduced body weight and nose-rump-
length as well as a significant increase of the kidney weight as compared to their 
controls. In GH transgenic mice in stage 2 only the body weight was significantly 
increased as compared to the control animals. The body weight of GH transgenic 
mice in stage 1 as well as kidney weight and nose-rump-length of GH transgenic 
mice in stage 1 and 2 were increased vs. the corresponding control animal data, but 
these differences did not reach statistical significance. This is probably due to the 
very young age when the growth hormone effect is not yet long enough to cause 
more profound alterations. As previously shown, differences in body and kidney 
weight between GH transgenic and control mice become significant at an age of 38 
days (Fisch, 2004). Creating well defined sample material is crucial for a good 
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proteomic analysis. Thus, we determined presence of absence of albuminuria as well 
as the mean glomerular volume of each transgenic animal and its corresponding 
control. Additionally, body weight, kidney weight and nose-rump-length were 
determined for each animal. Barati and colleagues (2007) chose a different approach 
for the creation of sample material. Mice were not selected by a defined disease 
stage, but according to their age. The presence of glomerular alterations as well as 
albuminuria was postulated, relying on experiences from earlier studies on mice of 
the same model. 
5.3 Glomerulus isolation 
Proteomic analysis was performed on isolated murine glomeruli instead of whole 
kidney samples due to several reasons. Early alterations in the course of progressive 
glomerulosclerosis become manifest in the glomeruli, but do not yet affect the rest of 
the kidney. Because glomeruli represent only about 2 – 4 % of the whole kidney 
volume in different species (Artacho-Perula et al., 1993; Nyengaard and Bendtsen, 
1992; Wanke, 1996), a subproteome approach targeting isolated renal glomeruli was 
the method of choice. A crucial demand for the glomerulus isolation was to obtain 
sufficient glomeruli from one mouse to run a 2D-gel based proteomic analysis. For a 
classical 2D-gel at least 100 – 200 µg total protein are needed. For the 2D-DIGE 
approach as used in this study about 75 µg protein are sufficient per sample (Berendt 
et al., 2005; Frohlich et al., 2006).  
Methods to isolate glomeruli from rats and rabbits using sieving techniques have 
already been described (Downer et al., 1988; Kreisberg et al., 1978). However, from 
mice it is difficult to isolate pure glomeruli by sieving, because the diameter of mouse 
glomeruli is relatively similar to their tubules (Takemoto et al., 2002). Fractional 
sieving or picking under a photomicroscope yield glomeruli, but far too less for a 
proteomic analysis. Isolation of mouse glomeruli after Fe3O4 perfusion has been 
reported, however the isolation efficiency was rather limited (Baelde et al., 1994).  
To overcome these problems a recently published method for large scale glomerulus 
isolation was used in the present study (Takemoto et al., 2002). The method was 
modified and optimized in order to obtain samples of reproducible quality and 
quantity. During this process beads from different manufacturers were tested and the 
best results could be achieved using Dynabeads® M-450 Epoxy (Invitrogen, 
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Germany). With other beads the perfusion could not be performed without difficulty, 
resulting in losses of either quality / purity or quantity of the glomerulus isolates. At 
the end, with a yield of ~20,000 glomeruli, virtually all glomeruli present in two mouse 
kidneys could be isolated in about 100 minutes with only minimal contamination by 
non-glomerular cells (Bonvalet et al., 1977; Takemoto et al., 2002). Once lysed, 
10,000 glomeruli yielded approximately 200 – 250 µg of total protein. Taken into 
account that two kidney slices and an aliquot for transcriptomic profiling were 
removed during the isolation procedure, about 250-300 µg total protein could be 
obtained from 11,000 – 13,000 glomeruli. This amount of protein proved to be 
sufficient to perform a differential proteomic analysis of glomeruli from each individual 
animal, avoiding a pooling of glomerular samples from different animals. The final 
protein amount was always dependent on size of the kidney slices, optimal perfusion 
as well as on losses during the washing steps. Sitek et al. (2006) could only obtain 
about 40 µg total protein from the glomeruli isolated out of one kidney with the same 
method. They also modified the original procedure of Takemoto et al. (2002) and 
perfused the kidneys directly with ice-cold PBS instead of 37°C warm PBS and only 
afterwards with Dynabeads. This might have led to a suboptimal perfusion and 
glomerulus isolation yield due to vasoconstriction of the preglomerular arterioles. 
Creating well defined sample material is crucial for a good proteomic analysis. 
Therefore, the quality and suitability for proteomic analysis was assessed in 
preliminary experiments during the optimization process. Additionally, glomeruli were 
isolated from a maximum of two mice per day in a narrow time-frame and under 
identical conditions.  
5.4 Proteomic approach 
Proteomic approaches targeting the differences in glomerular proteomes of healthy 
subjects and those with renal alterations have been very rare so far. Xu and 
colleagues (2005) revealed differences in the m/z patterns of sclerotic and non-
sclerotic glomeruli in 5/6 nephrectomized rat in a direct mass spectrometric 
approach. Very recently, alterations in the cellular redox pathways and advanced 
glycation end product metabolism in glomeruli of db/db diabetic mice were revealed 
by a 2D-gel based differential proteomic analysis (Barati et al., 2007). Other studies 
focused on cultured glomerular mesangial cells or podocytes, but not on isolated 
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glomeruli (Barati et al., 2006; Kuncewicz et al., 2003; Ransom et al., 2005). To our 
knowledge, the present study is the first study comparing the differences in 
glomerular proteomes of two murine nephropathy models. For the 2D-gels a pH-
gradient of 4-7 was chosen, because in this pH-gradient a sufficiently wide range of 
proteins can be separated. An increased resolution is provided as compared to a 
broader pH-gradient of 3-10, resulting in less comigration of proteins (Westbrook et 
al., 2001). Differences in the formats of the gels run with samples from GH transgenic 
mice and their controls and those run with samples from GIPRdn transgenic mice and 
their controls are due different systems in which the gels were run. After scanning the 
images were submitted to DeCyder software analysis. During this analysis spots in 
all gels were positionally matched to each other and the intensities of the fluorescent 
signals of transgenic and control images were compared. In this study only spots that 
were present in all gels, had an average abundance ratio of ± 1.5, and had a p-value 
of p < 0.01 were considered as differentially abundant. The p < 0.01 instead of 
p < 0.05 was set in order to keep up stringent conditions as they are usually used in 
this laboratory (Berendt et al., 2005; Frohlich et al., 2006). Stringent criteria are set to 
minimize the detection of false positive results, even though more false negative 
results have to be accepted at the same time (Tonge et al., 2001). The reproducibility 
of the study can be visualized best by the line charts and the 3D-volume plots of 
each of the biological replicates. In this study a good resolution of the spots as well 
as reproducible changes in the intensity of most spots among the different gels could 
be observed. In some spots, the absolute normalized abundance values of a 
biological replicate was different from that of the other replicates as could be traced 
in the line charts. However, the statistical p-value was finally the determining 
criterium and the respective spots were nonetheless included in the analysis. In 
software-based evaluation of 2D-gels, user defined parameters for selection filters 
have a major influence on the number of proteins indicated by the software to be 
differentially represented in different samples (Gade et al., 2003). Therefore, the 
comparison of the number of differentially abundant proteins in this study with that of 
other studies has to be done carefully. For example, Barati and colleagues (2007) 
found 40 spots to be increased in their abundance in glomeruli of diabetic mice, 
having set a p-value of < 0.05. In the glomeruli of GIPRdn transgenic mice 42 spots 
were considered as differentially abundant with a p-value of < 0.01. With a change in 
the p-value to < 0.05 about 90 would have been considered as differentially 
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abundant. The increased absolute number of differentially abundant proteins in 
GIPRdn transgenic mice in stage 2 vs. their controls as compared to GH transgenic 
mice in stage 2 vs. their controls – can be explained by a better resolution power of 
the Typhoon Scanner used for the gels which were run with samples from GIPRdn 
transgenic mice and controls, as compared to the Ettan™ DIGE Imager used for the 
gels which were run with samples from GH transgenic mice and controls. A 
considerable increase in the number of differentially abundant proteins can be 
observed in the gels of GH transgenic mice vs. their controls in stage 1 as compared 
to stage 2 (5 vs. 22). This suggests the beginning of substantial changes in the 
protein pattern with the onset of albuminuria in these mice, even though animals in 
stage 2 were only four to five days older than those in stage 1. Even more, it confirms 
the choice of the examined disease stages with the focus on the onset of albuminuria 
to be a reasonable decision for the detection of alterations at a very early time point. 
  
5.5 Identification of proteins  
For the identification of differentially abundant protein spots preparative gels were run 
for each group stained with colloidal Coomassie. The use of the analytical fluorescent 
gels is problematic, because once the gel has been removed from the fluorescent 
scanner, the spots are no longer visible and one would have no control which spot 
would be picked (Tonge et al., 2001). Additionally, spots that are visible in the 
Coomassie stained gels, can be precisely excised under visual control, providing a 
high chance of identification by MALDI-TOF/TOF analysis. In the group of GH 
transgenic mice vs. their controls one gel was run for both stages consisting of 
samples from both one transgenic and one control mouse. In the group of GIPRdn 
transgenic mice vs. their controls abundance ratios from -2.90 to +5.88 could be 
observered. To avoid underrepresentation of proteins in gels with pooled transgenic 
and control samples, separate gels of samples only from transgenic mice as well as 
only samples from control animals were run to achieve an optimal protein yield of 
picked spots. In order to obtain mass spectrometry spectra of optimal quality 
purification of peptides after tryptic hydrolysis of a protein prior to MALDI-TOF/TOF 
analysis is an important step (Lottspeich, 2006). For this purpose peptides were 
desalted and concentrated with pipette tips containing a miniature chromatography 
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column, so-called ZipTips. In the group of GIPRdn transgenic mice vs. their controls 
some spots were very weak in the gel and therefore they were analysed by nano LC-
MS/MS rather than MALDI-TOF/TOF analysis. The use of nano LC-MS/MS results in 
higher concentrations of the peptides derived from a protein spot reaching the MS-
detector due to very low flow rates of about 240 nl/min (Frohlich and Arnold, 2006). 
This leads to higher signal to noise ratios and therefore to an enhanced sensitivity of 
the overall system. The nano LC-MS/MS analysis in this study is more sensitive than 
the MALDI-TOF/TOF analysis, but it is also very time-consuming – about 30 minutes 
for the analysis of one spot as compared to an analysis time of only a few minutes 
using MALDI-TOF/TOF mass spectrometry. Thus, LC-MS/MS is not routinely used 
for spot identification. Not all differentially abundant spots could be picked from the 
preparative gels, because they were either not detectable in these gels, could not be 
clearly distinguished from neighbouring spots or could not be assigned to the spot 
from the analytical images. Spots can be undetectable in Coomassie stained gels 
due to the lower sensitivity of colloidal Coomassie compared to fluorescence and the 
differential staining of proteins with different staining methods (Frohlich et al., 2006; 
Tonge et al., 2001). Although 500 µg protein were applied (2D-DIGE: 50 µg per dye), 
this increased protein amount cannot completely compensate the low sensitivity of 
the Coomassie staining. Some of the picked spots could not be identified, probably 
due to very low protein concentration within the spot. Taken together, in the group of 
GH transgenic mice in stage 2 vs. their controls and GIPRdn transgenic mice in 
stage 2 vs. their controls about half of the differentially abundant spots could be 
successfully identified which could be observed in other studies as well (Frohlich et 
al., 2006; Tonge et al., 2001). Among them are several ambiguous identifications in 
which spots contain two or more different proteins. For these spots it cannot definitely 
be determined which of the proteins in the spot caused the differential abundance 
(Lilley et al., 2002) and had therefore to be excluded from further studies. Spots with 
several proteins are usually a result from comigration of proteins with similar 
molecular mass and pI (Westbrook et al., 2001). To further separate the proteins by 
their pI, gels with a narrower pH-gradient would have to be run. Molecular masses 
and pI of almost all unambiguously identified proteins as seen in the gel matched 
with the theoretical data, indicating that no protein degradation occurred during 
sample preparation (Gorg et al., 2004). However, in some cases differences in 
molecular mass or pI could be observed. If the molecular mass of a protein observed 
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in the gel is lower than indicated in the database, this is possibly a result of protein 
processing in the cell (Pratt et al., 2002). Generally, identification of proteins is being 
achieved by comparison of mass spectrometry data to the data of existing 
databases. Those databases include protein sequences that have been verified for 
the corresponding protein, but they also list sequences derived from cDNA. Often the 
sequence translated from cDNA into the sequence of amino acids includes the whole 
protein or precursor protein, which can be further processed in the cell, e.g. by 
cleavage of a leader peptide. Differences in pI can easily occur whenever a protein is 
posttranslationally modified. For example, phosphorylations will shift the pI to a more 
acidic region (Immler et al., 1998). 
Taken together, eight unique proteins could be identified in the group of GH 
transgenic mice in stage 2 vs. their controls and 13 unique proteins in the group of 
GIPRdn transgenic mice in stage 2 vs. their controls, respectively. Annexin A4, 
dihydropyrimidinase-related protein 2 (DRP-2), tropomyosin as well as myosin 
regulatory light chain 2 were differentially abundant in the glomeruli of transgenic 
mice in both analysed mouse models. Alterations in cellular redox pathways and 
advanced glycation end product metabolism were recently observed in the glomeruli 
of db/db diabetic mice (Barati et al., 2007). Among the identified altered proteins 
were a number of proteins related to oxidative stress, participating in the tricarboxylic 
acid cycle as well as cytoskeletal proteins. Vinculin and tropomyosin were the only 
differentially abundant proteins that could also be detected in the present study. But 
nevertheless, proteins of the same functional groups were identified in this study, 
including heat shock protein 60 (HSP 60), sarcosine dehydrogenase (SarDH) and 
succinate dehydrogenase (DHSA). SarDH and DHSA were recently found to be 
altered in renal cortex of diabetic db/db mice (Tilton et al., 2007) among a high 
percentage of other mitochondrial proteins as well as cytoskeletal proteins. These 
results are consistent with an earlier proteomic study of whole kidney lysates from 
another diabetic mouse model, in which identified differentiall abundant proteins 
belonged to similar functional groups (Thongboonkerd et al., 2004). Like in the 
present study, the smooth muscle contractile elements tropomyosin and myosin light 
chain were among the identified proteins. 
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Identified proteins – known and possible functions in glomerulosclerosis: 
 
Galectin-1 was increased in glomeruli of GH transgenic mice as compared to their 
controls. Galectins are a family of carbohydrate-binding proteins with an affinity for β-
galactosides and are involved in cell growth, apoptosis and cell migration features 
(Mathieu et al., 2005). Galectin-1 is differentially expressed by various normal and 
pathological tissues and has both intracellular and extracelluar functions (Camby et 
al., 2006). It has been found to be expressed in isolated human glomeruli as well as 
in cultured mesangial cells and podocytes in several proteomic studies (Jiang et al., 
2005; Ransom et al., 2005; Yoshida et al., 2005). Galectin-1 is highly expressed in 
human glomeruli, but not in tubuli (Uhlen et al., 2005). Apart from the lectin activity 
galectin-1 is involved in protein-protein interactions, binds to a number of extracelluar 
matrix (ECM) components, and plays a role in ECM assembly and remodeling 
(Camby et al., 2006). Galectin-1 is mitogenic for various cell types including 
mammalian vascular cells (Moiseeva et al., 2000). Recently it has been shown to 
play a critical role in angiogenesis and to be directly involved in endothelial cell 
proliferation and migration (Thijssen et al., 2006). Galectin-1 expression was 
increased in growth factor activated endothelial cells (Thijssen et al., 2006). 
Proliferation of endothelial cells in association with glomerular hypertrophy of GH 
transgenic mice has been demonstrated earlier (Wanke, 1996). Therefore, galectin-1 
could play an important role in the course of glomerular hypertrophy.  
 
Serum albumin was significantly increased in glomeruli of GH transgenic mice as 
compared to their controls. One possible reason would be that plasma or blood 
remained in the glomerular capillaries after the perfusion. The alterations in the 
abundance of glomeruli from transgenic animals as compared to the control animals 
are very consistent in every biological replicate. It is unlikely, that with every 
perfusion the same amount of blood would remain in the glomeruli of GH transgenic 
mice as well as the consistently lower amount in the glomeruli of control mice, which 
would be necessary to meet the statistically significant changes in abundance. 
Aditionally, a differential abundance of albumin between glomeruli of transgenic mice 
and those of controls were observed neither in GH transgenic mice in stage 1 nor in 
GIPRdn transgenic mice in stage 2 vs. their controls. The mesangium of the 
glomerulus has direct contact to the glomerular blood flow, because the endothelial 
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fenestrations open directly into the mesangium (Latta, 1992). This allows blood 
plasma to flow into the mesangium and plasma proteins like albumin to bind to the 
mesangial matrix. Deposits of increased amounts of normal components are 
recognized in glomerulosclersosis (Latta, 1992). It has been shown, that serum 
concentrations of total proteins are elevated in GH transgenic mice at an comparable 
age despite progressive renal protein loss (Fisch, 2004). This result is in line with 
previous findings in several GH transgenic mouse strains and is regarded as a result 
of increased hepatic protein synthesis (Brem et al., 1989; Wanke, 1996). In addition, 
albumin could be detected in the cytoplasm of podocytes of GH transgenic mice 
(Wanke, 1996). With albumin being the most abundant plasma protein an 
accumulation of albumin in the glomeruli of GH transgenic mice seems to be 
explainable, but still the question remains, in which part exactly it is accumulating, 
mesangium or podocytes.  
 
Fibrinogen gamma chain has shown to be increased in the glomeruli of GIPRdn 
transgenic animals as compared to their controls. It is part of the fibrinogen which 
represents a heterohexamer containing two sets of three non-identical chains 
(α, β, γ). Increased glomerular fibrinogen deposition has been described in the 
remnant kidney model (Floege et al., 1992). Additionally, it is well known that in early 
stages of diabetic nephropathy (in type 1 and type 2 diabetes mellitus) fibrinogen 
levels in plasma are elevated which could lead to a deposition of fibrinogen in the 
glomeruli. There is also a correlation between the plasma level and albumin excretion 
in the urine (Klein et al., 2003; Lengyel et al., 2004; Tessari et al., 2006). Fibrinogen 
binds intimately to fibronectin (Colvin et al., 1979) which has been shown to play a 
critical role in the development of glomerulosclerosis and to be increased in sclerotic 
glomeruli (Shui et al., 2006). In the glomeruli of GIPRdn transgenic mice an increased 
deposition of fibronectin could also be demonstrated (Herbach, 2002; Schairer, 
2006). Therefore, an increased binding of fibrinogen to fibronectin is likely and in 
combination with the presumption that diabetic mice display high levels of fibrinogen 
in plasma like humans, an increase in fibrinogen in glomeruli of GlPRdn transgenic 
mice is explainable. A further aspect to be looked on is the fact, that vascular 
endothelial growth factor (VEGF) obviously binds to fibrinogen and thereby 
stimulates endothelial cell proliferation (Sahni and Francis, 2000). VEGF is implicated 
in the development of proteinuria during diabetic nephropathy (Xia et al., 2007). 
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Glomerular hypertrophy is partly due to proliferation of endothelial cells and 
enhanced angiogenesis takes place in diabetic nephropathy (Wanke, 1996; Zent and 
Pozzi, 2007). In conclusion changes in glomerular fibrinogen levels could contribute 
to the pathogenetic processes in glomerular hypertrophy and albuminuria.  
 
The heat shock protein 60 (HSP60) which was increased in glomeruli of GIPRdn tg 
mice plays a major role in the folding and assembly of mitochondrial proteins and is 
exclusively detectable in mitochondria in the kidney (Muller et al., 1996). Even though 
HSP60 couldn’t be localized in glomeruli by an immunhistochemical study (Muller et 
al., 1996), it has been found in several proteomic analyses of isolated human 
glomeruli (Yoshida et al., 2005), cultured mesangial cells as well as podocytes (Jiang 
et al., 2005; Ransom et al., 2005). In kidneys of rats with streptozotocin (STZ) 
induced diabetes mellitus it has recently been shown that the expression of HSP60 
mRNA as well as the protein content is increased, probably due to increased 
oxidative stress in the context of diabetic metabolism (Oksala et al., 2007). An 
additional function of HSP60 is its ability to activate endothelial cells by an increase 
of the proinflammatory cytokine interleukin-6 and the induction of nuclear factor-κB 
(NF-κB) (Kol et al., 1999). The activation of NF-κB has been suggested to be an 
important step during diabetic nephropathy (Iwamoto et al., 2005; Schmid et al., 
2006). Therefore, an increase of HSP60 might play a role as pathogentic factor in the 
course of diabetic nephropathy.  
 
Another two mitochondrial proteins were increased in their abundance in glomeruli of 
GIPRdn transgenic mice, sarcosine dehydrogenase and the flavoprotein subunit of 
the succinate dehydrogenase. Sarcosine dehydrogenase, highly expressed in the 
kidney, is a mitochondrial flavoenzyme involved in the oxidative degradation of 
choline to glycine which takes place in mitochondria (Bergeron et al., 1998). As many 
other mitochondrial proteins it has been shown to differ in its abundance in renal 
cortex of diabetic subjects, suggesting an altered mitochondrial metabolism during 
diabetes (Tilton et al., 2007). The flavoprotein subunit of the succinate 
dehydrogenase (SDH) is one of four subunits of this enzyme. SDH is involved in the 
tricarboxylic acid cycle and represents the complex II in the respiratory chain in the 
inner mitochondrial membrane. Like sarcosine dehydrogenase it has been found to 
be altered in diabetic renal cortex (Tilton et al., 2007). In mitochondria of renal cortex 
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of rats with STZ induced diabetes SDH activity was dramatically elevated after one 
month of diabetes. This was suggested to be a compensatory effect, because 
hypertrophic processes are energy dependent (Katyare and Satav, 2005).  
 
Bleomycin hydrolase, which was decreased in the glomeruli of GIPRdn transgenic 
mice, was originally discovered as an enzyme that inactivates the anticancer drug 
bleomycin (Sebti et al., 1989). It is widely distributed in many tissues, with highest 
activities in kidney and liver (Filderman and Lazo, 1991; Kamata et al., 2007), but its 
physiological function is yet to be unknown. Recently, a study has revealed its 
function as an intracellular homocysteine-thiolactonase which protects cells against 
homocysteine toxicity (Zimny et al., 2006). Homocysteine is known to induce 
endothelial dysfunction and hyperhomocysteinemia has been associated with 
microalbuminuria in diabetic patients (Huijberts et al., 2005; Ozmen et al., 2002). A 
decrease in bleomycin hydrolase as seen in the present study could therefore 
enhance homocysteine toxicity and contribute to the development of 
microalbuminuria. 
 
Eukaryotic translation initiation factor 3 subunit 1 (eiF-3 alpha) was increased in the 
glomeruli of GIPRdn transgenic mice and it represents one of at least ten subunits of 
eiF-3. EiF-3 is a large multisubunit complex that plays a central role in the initiation of 
translation (Block et al., 1998). It hasn’t been described in connection with 
glomerulosclerosis or diabetic nephropathy, but its increased abundance in GIPRdn tg 
mice might be associated with the mammalian target of rapamycin (mTOR) pathway. 
Eif-3 seems to mediate mTOR’s role in translation initiation (Lee et al., 2007). mTOR 
is normally inactive in the kidney, but its activation plays an essential role in 
hypertrophic responses to insults like diabetes and compensatory renal hypertrophy, 
because mTOR activity stimulates cell growth and proliferation (Weimbs, 2006). 
Furthermore, the mTOR pathway has been shown to be activated in diabetic 
glomeruli and mediates mesangial cell hypertrophy (Nagai et al., 2005). Therefore an 
upregulation of eiF-3 might play a role in activation of the mTOR pathway and in the 
hypertrophic processes in the glomeruli.  
 
Ig kappa chain C region was found to be increased in the glomeruli of GIPRdn 
transgenic mice as compared to their controls. In the present study there is a 
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discrepancy between the molecular mass observed in the gel (approx 23 kDa) and in 
the database (approx 12 kDa). An Ig light chain consists of a constant (C) and a 
variable region. The protein identified is the C region of the kappa chain, but the 
higher molecular mass could be explained by the presence of the variable region 
which is not identified in the database. In a recent study Ig kappa chain was markedly 
increased in the plasma of rats with STZ induced diabetes (Kim et al., 2006). In 
patients with diabetes mellitus increased urinary excretion of Ig kappa light chains 
has been reported (Groop et al., 1990). In longstanding diabetes its excretion was 
positively correlated with urinary albumin excretion. An accurate mechanism 
responsible for increased levels remains uncertain. Glycation of kappa light chains is 
a known event and the glycated kappa light chains tend to form high molecular 
polymers (Groop et al., 1990). These polymers can’t be freely filtered through the 
glomerular filtration barrier and an increase in kappa light chains in glomeruli of 
diabetic mice might be due to increased deposition of these polymers within the 
glomerulus.  
 
Complement C4 B was increased in glomeruli of GIPRdn transgenic mice. In this 
study there is a discrepancy between the mass observed in the gel (22 kDa) and the 
one in the database (193 kDa). The mass in the database refers to the whole C4 B 
precursor, but in the gel there is probably only a fragment of it which would explain 
the smaller mass. C4b is a major activation product in the classical pathway of the 
complement system. It is an essential subunit of the C3 convertase (C4b2a) and the 
C5 convertase (C3bC4b2a) enzymes. The complement system plays an important 
role in the pathogenesis of diabetic complications one of which is diabetic 
nephropathy (Ostergaard et al., 2005). An increased deposition of complement C3 in 
glomeruli has been shown in different animal models of diabetes (Fujita et al., 1999; 
Mauer et al., 1972; Mauer et al., 1974; Michels et al., 1984; Wehner et al., 1972). The 
mechanism for an activation of the complement system in diabetic patients are still 
not known. Activation through intracellular generation of reactive oxygen species are 
considered as well as the fact that injured glomeruli bind to Ig and activate the 
complement system which seems to exacerbate glomerulosclerosis (Fujita et al., 
1999; Ostergaard et al., 2005). With C4b being part of the complement pathway a 
deposition in diabetic glomeruli could be considered even though this hasn’t been 
directly demonstrated yet. Plasma levels of C4, however, seem to be significantly 
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lower in about 25 % of diabetic patients despite a high level of C3 fragments 
indicating activation of complement. In addition there is a high prevalence of 
microalbuminuria in patients with low C4 levels (Barnett et al., 1984; Chiarelli et al., 
1988). 
 
Cytoskeletal proteins are high abundant proteins within glomerular cells and the 
cytoskeleton plays a very important role in maintaining the cells shape and motility. 
Especially in podocytes and mesangial cells a tight regulation of the cytoskeleton is 
necessary to keep up their special functions in the glomerulus, i.e. glomerular 
filtration barrier and mechanical support against the hydraulic pressures in the 
capillaries (Kriz et al., 1990). In the present study several cytoskeletal proteins were 
found to be altered in transgenic animals as compared to their controls in both mouse 
models and all of them showed an increased abundance. Hypertrophy of cells always 
comes along with an increased protein synthesis and larger cells need a stronger 
cytoskeleton to maintain shape and function. Cytoskeletal rearrangement, especially 
in the actin cytoskeleton, has been well described in the context of 
glomerulosclerosis in podocytes as well as in mesangial cells (El Nahas, 1996; 
Pavenstadt et al., 2003; Shankland, 2006; Simonson, 2007). Two members of the 
contractile apparatus, tropomyosin and myosin regulatory light chain 2 (MLRC2), 
were increased in the glomeruli of both GH transgenic and GIPRdn transgenic mice. 
Nonmuscle myosin II plays an essential role in actin cytoskeleton organization and 
cellular motility (Watanabe et al., 2007). Myosin heavy chains have been 
demonstrated to be increased in hypertrophic glomeruli (Hiroi et al., 1996). As 
MLRC2 is part of the whole myosin II, an increase is likely, too. The exact isoform of 
the tropomyosin found in the gels could not be determined by the database results, 
but due to the highest protein score and distinct MS/MS peptide it is likely to be 
tropomyosin-1 (TPM-1), although a mixture of several isoforms cannot be ruled out. 
TPM-1 is the major isoform in mesangial cells (Ishino et al., 1991). It hasn’t been 
directly described in the context of glomerulosclerosis, but increased flows and 
hypertrophy make increased demands on the contractile apparatus of the glomerular 
cells (Kriz et al., 1990).  
Vinculin and filamin-A, two important proteins in the organization of the actin 
cytoskeleton, were increased only in the glomeruli of GH transgenic mice. In the gels 
of GIPRdn transgenic mice vs. their controls – run on a different electrophoretic 
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equipment – proteins of such a high molecular weight were not well resolved and 
could therefore not be detected as altered. So it is still possible, that these proteins 
are also altered in GIPRdn transgenic mice. Vinculin links the actin filaments to the 
integrins in the basement membrane. An increased recruitment of vinculin has been 
associated with cellular responses to mechanichal stress applied to ligand-bound 
integrins by enlarging their focal adhesions (Ziegler et al., 2006). This has also be 
shown in TGF-β stimulated mesangial cells (Hubchak et al., 2003). Filamin-A plays 
an important role in crosslinking actin filaments as well as in signalling towards 
changes in cytoskeletal rearrangements (Popowicz et al., 2006). Changes in the 
actin cytoskeleton are likely to involve this protein. DRP-2 also represents an actin 
binding protein in addition to its functions mentioned below.  
Several spots in the group of GIPRdn transgenic mice vs. their controls have been 
identified as actin, but like tropomyosin the exact isoform couldn’t be determined by 
the database search. The highest protein score and the matching of at least one 
distinct peptide suggest the presence of cytoplasmic actin, but other isoforms could 
be present as well. Molecular mass and pI in the gel are mostly consistent with 
database results, but spot 40 has a very low molecular weight and in this case it is 
likely that only a fragment of actin is present in the actual spot. Smooth muscle-alpha 
actin is known to be increased in activated mesangial cells and also in hypertrophic 
glomeruli (Floege et al., 1992). Although most of the altered cytoskeletal proteins 
have already been described in the glomerulosclerotic process, it is still unclear, 
whether they only represent the occurring structural changes or might also play a role 
in the pathogenesis of glomerulosclerosis.  
 
Annexin A4 was found to be decreased in glomeruli of both GH and GIPRdn 
transgenic mice. It has high expression levels in the kidney and is predominantly 
found in epithelial cells (Dreier et al., 1998; Markoff and Gerke, 2005). Annexin A4 
has been detected in tubuli and Bowman’s capsule as well as in cultured podocytes 
and mesangial cells (Dreier et al., 1998; Jiang et al., 2005; Ransom et al., 2005). 
This calcium binding protein hasn’t been described in the context of 
glomerulosclerosis yet, but it seems to be involved in several functions in the kidney 
including kidney development, membrane organization and the regulation of calcium-
activated epithelial chloride channels (Markoff and Gerke, 2005). Studies on Annexin 
A4a deficient mice revealed striking morphological alterations in the kidney and 
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suggested an important role for this protein in kidney development (Li et al., 2003). 
This is supported by a study on Xenopus laevis, in which downregulation of Annexin 
A4 led to a disturbed development of pronephric tubules (Seville et al., 2002). As 
mentioned above it has been shown that annexin A4 plays an inhibitory role in the 
regulation of calcium-activated epithelial chloride (Cl-) conductance (Kaetzel et al., 
1994). Inhibition of annexin A4 leads to an increase in Cl- conductance. Interestingly, 
studies on podocytes in the intact glomerulus of the rat revealed that angiotensin II 
(Ang II) depolarized podocytes by opening a Cl- conductance and that this process 
may be regulated by intracellular calcium activity (Gloy et al., 1998). It is known that 
Ang II increases the cytosolic calcium activity in cells (Gloy et al., 1998) and 
contributes to the pathogenesis of glomerulosclerosis (Fogo, 1994; Kriz et al., 1994). 
Annexin A4 might be involved in the process of the Ang II related depolarization of 
podocytes. Its decreased abundance could diminish the inhibitory effect and increase 
the Ang II effect of influencing the contractile state of podocyte foot processes. 
Recently, Annexin A4 has been shown to form a complex with rabphilin and 
synaptotagmin in neurons, suggesting a possible role in synaptic exocytosis 
(Willshaw et al., 2004).  Because podocytes seem to be related to neurons 
(Kobayashi et al., 2004; Rastaldi et al., 2003), there might be another role for annexin 
A4 in these cells. Taken together, annexin A4 seems to be an interesting candidate 
protein and further studies will reveal possible functions in the glomerulus.  
 
The other protein which was decreased in glomeruli of GH transgenic as well as of 
GIPRdn transgenic mice is the dihydropyrimidinase related protein-2 (DRP-2) also 
known as collapsing response mediator protein 2 (CRMP-2). Except for the liver 
DRP-2 is widely expressed in different tissues, with highest levels in the brain 
(Hamajima et al., 1996). Most of the knowledge on the biological significance of 
DRP-2 has been in the context of its function in neurons. However, a recent study 
could demonstrate that DRP-2 is involved in signalling pathways that regulate the 
proliferation of non-neuronal cells with phosphorylation of DRP-2 playing an 
important role (Tahimic et al., 2006). DRP-2 hasn’t been described in the context of 
glomerular alterations, but it has been detected in cultured podocytes and glomeruli 
by proteomic analysis (Ransom et al., 2005; Yoshida et al., 2005). Because 
podocytes share many cell biological characteristics with neurons (Kobayashi et al., 
2004; Rastaldi et al., 2003), it is interesting to look on the neuronal functions of DRP-
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2. DRP-2 has emerged as a crucial regulator of microtubule dynamics during 
neurite/axonal growth (Fukata et al., 2002). Non-phosphorylated DRP-2 binds with 
high affinity to tubulin heterodimers and enhances microtubule formation (Arimura et 
al., 2005). Phosphorylation by Rho-kinase has been shown to prevent the 
association of DRP-2 with tubulin dimers thereby having a negative effect on DRP-2 
function (Arimura et al., 2005; Mimura et al., 2006). In podocytes, microtubules are 
essential for an intact structure of major podocyte processes, connecting the cell 
body with the GBM-anchored actin network in foot processes and disruption of 
microtubules results in severe damage of the major processes (Pavenstadt et al., 
2003). For Rho-kinase has been shown to be involved in the development of 
glomerulosclerosis (Hayashi et al., 2006) and plays a pivotal role in the formation of 
podocyte processes (Kobayashi et al., 2004), decreased levels of DRP-2 or 
phosphorylation could be involved in podocyte injury. In the present study three spots 
in the glomeruli of GH transgenic mice were identified as DRP-2 which only differed 
in their pI, indicating different phosphorylation states of the protein. In conclusion, 
DRP-2 seems to be a very interesting candidate protein and further studies will be 
necessary to clarify the exact localization and function of DRP-2 within the 
glomerulus.  
 
In summary, the differential proteomic analysis of well defined glomerulus samples of 
GH transgenic mice and their controls as well as of diabetic GIPRdn transgenic mice 
and their controls was successfully performed. Out of eight identified differentially 
abundant proteins in the group of GH transgenic mice in stage 2 vs. their controls 
and out of 13 identified proteins in the group of GIPRdn transgenic mice in stage 2 vs. 
their controls, respectively, an intersection of four proteins could be build. Two of 
these proteins, annexin A4 and DRP-2, represent promising candidate proteins on 
which further hypothesis driven studies should be performed. 
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6. Perspective 
Differential proteomic analysis of glomeruli from two murine models of nephropathy 
revealed a number of differentially abundant proteins in the stage of glomerular 
hypertrophy together with a beginning albuminuria in each of the analysed models. 
Annexin A4 and DRP-2, two of the proteins that were differentially abundant in the 
glomeruli of GH transgenic mice in stage 2 vs. their controls and GIPRdn transgenic 
mice in stage 2 vs. their controls, are of interest for further hypothesis driven 
investigations. The exact localization of these proteins within the glomerulus as well 
as a confirmation of the altered abundances applying immunohistochemistry will be 
essential to go into detail about possible roles and functions of the proteins in the 
course of glomerular hypertrophy and albuminuria. Genetically modified mice would 
be of immense use for further functional studies. 
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7. Summary 
The present study focuses on progressive glomerulosclerosis which is known as a 
complication of a variety of systemic diseases and plays a crucial role in the 
progression of chronic renal failure. Therefore, the study of the pathogenesis of 
progressive glomerulosclerosis is a key issue in nephrologic research. Precursor 
lesions of glomerulosclerosis include the development of glomerular hypertrophy 
followed by albuminuria. The present study addressed the question, whether these 
early glomerular alterations lead to differences in the abundance levels of distinct 
proteins in the glomeruli. Therefore, the glomerular proteomes of two different mouse 
models of nephropathy were analysed at defined stages of renal alterations. Because 
glomeruli represent only about 2 – 4 % of the whole kidney volume, a subproteome 
approach targeting isolated renal glomeruli was the method of choice. The first 
mouse model, growth hormone (GH) transgenic mice, are a well characterized model 
for progressive glomerulosclerosis. The second mouse model, diabetic transgenic 
mice expressing a dominant negative glucose-dependent insulinotropic polypeptide 
receptor (GIPRdn), represent a model for diabetes-associated glomerular lesions. 
Both transgenic mouse models develop glomerular hypertrophy and albuminuria. 
Pairs of male transgenic mice and their corresponding non-transgenic littermate 
control animals were investigated in the stage of glomerular hypertrophy together 
with a beginning albuminuria (stage 2). In GH transgenic and corresponding control 
mice the additional stage of glomerular hypertrophy without albuminuria was 
investigated (stage 1). To judge the degree of glomerular hypertrophy in an objective 
manner, the mean glomerular volume of the transgenic animals as compared to the 
respective controls was determined by quantitative stereological analysis. The onset 
of albuminuria in transgenic animals in stage 2 was determined by SDS-PAGE based 
analyses of urine samples taken on consecutive time points and was confirmed by 
Western blot and ELISA analyses. Glomerulus isolation was performed in a magnetic 
field after perfusion of the kidneys with spherical superparamagnetic beads, enabling 
a very high yield of approximately 10,000 glomerlui per mouse kidney within 100 
minutes. For differential quantitative proteomic analysis of glomerular proteomes 
from GIPRdn transgenic as well as GH transgenic mice versus their corresponding 
wild-type controls, the two dimensional difference gel electrophoresis (2D-DIGE) 
technique was applied in a pH gradient of 4-7. Differentially abundant spots were 
identified by matrix assisted laser desorption ionization – time of flight / time of flight 
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(MALDI-TOF/TOF) mass spectrometry analysis. Five differentially abundant protein 
spots were detected in GH transgenic mice in stage 1 as compared to their controls, 
but none of these spots could be unambiguously identified. Analysis of glomeruli from 
GH transgenic mice in stage 2 vs. those of the corresponding controls revealed 22 
differentially abundant protein spots. Eight proteins could be unambiguously 
identified and three spots contained two or more proteins. Analyzing the glomeruli of 
GIPRdn transgenic mice in stage 2 vs. those of the corresponding controls, a number 
of 42 differentially abundant protein spots could be detected, and out of them 13 
proteins could be unambiguously identified. Another seven spots were identified with 
mixed identities, containing two or more proteins. Most of the identified proteins have 
protein binding function or belong to the cytoskeleton. Molecular functions of other 
proteins include calcium ion binding, hydrolase activity or transporter activity. By 
comparison of the eight identified proteins in the group of GH transgenic mice and 
the 13 identified proteins in the group of GIPRdn transgenic mice an intersection of 
four identical proteins could be build (Tropomyosin, Myosin regulatory light chain 2, 
Annexin A4 as well as dihydropyrimidinase-related protein 2). Tropomyosin and 
Myosin regulatory light chain 2 represent structural constituents of the cytoskeleton 
which is known to undergo alterations in the course of glomerular growth processes. 
Annexin A4 and dihydropyrimidinase-related protein 2 (DRP-2) have not yet been 
described in the context of the development of glomerular lesions. But both of them 
have been shown to be present in neuronal cells. Because podocytes are known to 
share many similarities to neurons, the question arises, which kind of functions these 
proteins have in glomerular podocytes and in glomerular growth processes.  
The results of the present study provide an excellent basis for further hypothesis-
driven approaches aiming at a better understanding of the molecular mechanisms 
involved in glomerular growth processes and the pathogenesis of glomerulosclerosis.  
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8. Zusammenfassung 
Im Mittelpunkt der vorliegenden Arbeit steht die progressive Glomerulosklerose, die 
als Komplikation diverser systemischer Grundkrankheiten bekannt ist sowie eine 
entscheidende Rolle bei der Progression der chronischen renalen Insuffizienz spielt. 
Die Pathogenese der progressiven Glomerulosklerose stellt daher einen nephro-
logischen Forschungsschwerpunkt dar. Die Vorläuferläsionen der Glomerulosklerose 
beinhalten die Entwicklung einer glomerulären Hypertrophie gefolgt vom Auftreten 
einer Albuminurie. In der vorliegenden Studie wurde die Fragestellung bearbeitet, ob 
sich Frühstadien der Glomerulosklerose-Entwicklung auf Proteinebene wider-
spiegeln. Aus diesem Grund wurde das glomeruläre Proteom zweier muriner 
Nephropathiemodelle in definierten Stadien renaler Veränderungen analysiert. Es 
wurde ein Subproteomansatz gewählt, der ausschließlich isolierte Glomerula 
beinhaltet. Bei den beiden murinen Nephropathiemodellen handelt es sich zum einen 
um Wachstumshormon (GH) – transgene Mäuse, die ein gut charakterisiertes Modell 
für die progressive Glomerulosklerose darstellen und zum anderen um diabetische 
transgene Mäuse, die einen dominant negativen glucose-dependent insulinotropic 
polypeptide Rezeptor (GIPRdn) exprimieren und ein Modell für Diabetes-assoziierte 
Nierenschäden repräsentieren. Beide transgene Mausmodelle entwickeln eine 
glomeruläre Hypertrophie und eine Albuminurie. Paare von männlichen transgenen 
Mäusen und deren korrespondierenden Wildtyp Kontrolltieren wurden im Stadium 
der glomerulären Hypertrophie zusammen mit einer beginnenden Albuminurie 
(Stadium 2) untersucht. GH transgene Mäuse und ihre Kontrollen wurden zudem 
noch im vorausgehenden Stadium der glomerulären Hypertrophie ohne Albuminurie 
(Stadium 1) analysiert. Zur Beurteilung der glomerulären Hypertrophie erfolgte die 
Bestimmung des mittleren Glomerulumvolumens mittels quantitativ stereologischer 
Methoden. Das Einsetzen der Albuminurie in transgenen Tieren im Stadium 2 wurde 
anhand einer SDS-PAGE basierten Urinproteinanalyse bestimmt. Die dafür nötigen 
Urinproben wurden an definierten aufeinanderfolgenden Zeitpunkten gewonnen. Das 
Vorliegen einer Albuminurie wurde mittels Western Blot und ELISA Analysen 
bestätigt. Die Glomerula wurden nach Perfusion der Nieren mit sphärischen 
superparamagnetischen Beads in einem Magnetfeld isoliert. Dieses ermöglichte eine 
sehr hohe Ausbeute von ca. 10.000 Glomerula pro Mausniere in etwa 100 Minuten. 
Die differentiell quantitative Analyse des glomerulären Proteoms von GH transgenen 
und GIPRdn transgenen Mäusen im Vergleich zu ihren jeweiligen Kontrolltieren 
Zusammenfassung 107
erfolgte mittels der zweidimensionalen Differenz-Gelelektrophorese in einem pH-
Gradienten von 4 – 7. Differentiell abundante Proteinspots wurden mit Matrix 
assistierter Laser Desorptions Ionisations Tandem-Massenspektrometrie (MALDI-
TOF/TOF) identifiziert. Bei GH transgenen Mäusen im Stadium 1 konnten im 
Vergleich zu den Kontrolltieren fünf differentiell abundante Proteinspots nachge-
wiesen werden, allerdings ließ sich keiner dieser Spots eindeutig identifizieren. Die 
Analyse von Glomerula GH transgener Mäuse im Stadium 2 ergab im Vergleich zu 
den Kontrollen 22 differentiell abundante Proteinspots. Aus diesen Spots konnten 
acht Proteine zweifelsfrei identifiziert werden, in drei Spots waren zwei oder mehr 
Proteine enthalten. Bei GIPRdn transgenen Mäusen ergab die Analyse des 
glomerulären Proteoms im Vergleich zu den entsprechenden Kontrollen 42 
differentiell abundante Spots, aus diesen 13 Proteine eindeutig identifiziert werden 
konnten. In sieben der 42 Spots waren wiederum Mischungen aus zwei oder mehr 
Proteinen zu finden. Die meisten der identifizierten Proteine haben proteinbindende 
Funktion oder repräsentieren Komponenten des Zytoskeletts. Molekulare Funktionen 
anderer identifizierter Proteine beinhalten Kalziumionen- bindende Funktion, 
Hydrolaseaktivität oder Transporteraktivität. Durch Vergleich der acht identifizierten 
Proteine in der Gruppe der GH transgenen Mäuse mit den 13 identifizierten 
Proteinen in der Gruppe der GIPRdn transgenen Mäuse, konnte eine Schnittmenge 
von vier identischen Proteinen (Tropomyosin, Myosin regulatory light chain 2, 
Annexin A4 sowie Dihydropyrimidinase-related protein 2) gebildet werden. 
Tropomyosin und Myosin regulatory light chain 2 repräsentieren zytoskeletale 
Proteine. Annexin A4 und Dihydropyrimidinase-related protein 2 (DRP-2) sind bislang 
noch nicht im Zusammenhang mit der Entwicklung glomerulärer Läsionen 
beschrieben worden. Allerdings ist das Vorkommen dieser beiden Proteine in 
neuronalen Zellen bekannt. Da zwischen Podozyten und Neuronen große 
Übereinstimmungen bestehen, stellt sich die Frage nach den Funktionen von 
Annexin A4 und DRP-2 in glomerulären Podozyten sowie im Rahmen glomerulärer 
Wachstumsprozesse. Die Ergebnisse der vorliegenden Arbeit liefern die Basis für 
weiterführende, hypothesengetriebene Forschungsansätze zur Klärung der an 
glomerulären Wachstumsprozessen und der Entwicklung glomerulosklerotischer 
Alterationen beteiligten molekularen Mechanismen.  
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10. Attachment 
10.1 Silver stain for SDS-PAGE mini gels 
1. Fixation solution      60 minutes 
99.6 % Ethanol     500 ml 
Glacial acetic acid (Applichem, Germany) 120 ml 
37 % Formaldehyde (Applichem, Germany) 0.5 ml 
ad 1000 ml distilled water 
2. Washing in 50 % ethanol    3 times 20 minutes 
Pre-treatment     1 minute 
Sodium thiosulfate (Applichem, Germany) 0.05 g 
in 50 ml distilled water 
3. Washing in distilled water    3 times 20 seconds 
Impregnation     20 minutes 
Silver nitrate (Applichem, Germany)  0.05 g 
37 % Formaldehyde    37 µl 
ad 50 ml distilled water 
4. Washing in distilled water    2 times 20 seconds 
Develop      until bands become visible 
Sodium carbonate (Merck, Germany)  3 g 
Sodium thiosulfate     0.2 mg 
37 % Formaldehyde    50 µl 
ad 100 ml distilled water 
5. Washing in distilled water    20 seconds 
Stop solution 
0.1 M EDTA (Sigma, Germany) 
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10.2 Staining procedures for plastic embedded sections 
10.2.1 Hemalaun & Eosin (H&E) 
1. Mayer’s hemalaun (Applichem, Germany)   30 minutes 
2. Rinse in tap water      10 minutes 
3. 1 % HCl-Alcohol      1 second 
4. Rinse in tap water      10 minutes 
5. Dry 
6. Eosine Y (Merck, Germany)     5 minutes 
7. Distilled water       3 times 3 seconds 
8. Dry 
9. Mount with glass cover slips using Histofluid® (Superior, Germany) 
10.2.2 Periodic acid-Schiff stain (PAS) 
1. 1 % periodic acid (Applichem, Germany)  15 minutes 
2. Distilled water      3 times 3 seconds 
3. Schiff’s reagent (Merck, Germany)   30-60 minutes 
4. Rinse in tap water     30 minutes 
5. Dry 
6. Mayer’s hemalaun (Applichem, Germany)  35 minutes 
7. Rinse in tap water      10 minutes 
8. 1 % HCl alcohol      1 second 
9. Rinse in tap water      10 minutes 
10. Dry 
11. Mount under glass cover slips using Histofluid® (Superior, Germany) 
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10.3 PMF spectra of unambiguously identified differentially abundant spots 
10.3.1 GH transgenic mice in stage 2 vs. their controls 
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Spot 1, GH transgenic mice vs. their controls 
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Spot 2, GH transgenic mice vs. their controls 
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Spot 6, GH transgenic mice vs. their controls 
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Spot 7, GH transgenic mice vs. their controls 
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Spot 8, GH transgenic mice vs. their controls 
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Spot 11, GH transgenic mice vs. their controls 
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Spot 15, GH transgenic mice vs. their controls 
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Spot 19, GH transgenic mice vs. their controls 
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Spot 20, GH transgenic mice vs. their controls 
 
10.3.2 GIPRdn transgenic mice in stage 2 vs. their controls 
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Spot 1, GIPRdn transgenic mice vs. their controls 
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Spot 3, GIPRdn transgenic mice vs. their controls 
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Spot 7, GIPRdn transgenic mice vs. their controls 
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Spot 10, GIPRdn transgenic mice vs. their controls 
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Spot 13, GIPRdn transgenic mice vs. their controls 
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Spot 16, GIPRdn transgenic mice vs. their controls 
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Spot 17, GIPRdn transgenic mice vs. their controls 
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Spot 18, GIPRdn transgenic mice vs. their controls 
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Spot 22, GIPRdn transgenic mice vs. their controls 
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Spot 24, GIPRdn transgenic mice vs. their controls 
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Spot 28, GIPRdn transgenic mice vs. their controls 
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Spot 35, GIPRdn transgenic mice vs. their controls 
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Spot 40, GIPRdn transgenic mice vs. their controls 
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Spot 42, GIPRdn transgenic mice vs. their controls 
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